<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">85289</article-id><article-id pub-id-type="doi">10.7554/eLife.85289</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Lipid hydroperoxides promote sarcopenia through carbonyl stress</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-298155"><name><surname>Eshima</surname><given-names>Hiroaki</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4492-5892</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund19"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-300032"><name><surname>Shahtout</surname><given-names>Justin L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4111-4293</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-298151"><name><surname>Siripoksup</surname><given-names>Piyarat</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund14"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-302514"><name><surname>Pearson</surname><given-names>MacKenzie J</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-298157"><name><surname>Mahmassani</surname><given-names>Ziad S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund11"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-301748"><name><surname>Ferrara</surname><given-names>Patrick J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund17"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-300035"><name><surname>Lyons</surname><given-names>Alexis W</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-186913"><name><surname>Maschek</surname><given-names>John Alan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300036"><name><surname>Peterlin</surname><given-names>Alek D</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2837-7446</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-300037"><name><surname>Verkerke</surname><given-names>Anthony RP</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund15"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-300038"><name><surname>Johnson</surname><given-names>Jordan M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund16"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-300039"><name><surname>Salcedo</surname><given-names>Anahy</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-300040"><name><surname>Petrocelli</surname><given-names>Jonathan J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund13"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-300041"><name><surname>Miranda</surname><given-names>Edwin R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-153236"><name><surname>Anderson</surname><given-names>Ethan J</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-94820"><name><surname>Boudina</surname><given-names>Sihem</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-300042"><name><surname>Ran</surname><given-names>Qitao</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-162284"><name><surname>Cox</surname><given-names>James E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-298158"><name><surname>Drummond</surname><given-names>Micah J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-298159"><name><surname>Funai</surname><given-names>Katsuhiko</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3802-4756</contrib-id><email>kfunai@utah.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund18"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r0ha626</institution-id><institution>Diabetes and Metabolism Research Center, University of Utah</institution></institution-wrap><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r0ha626</institution-id><institution>Molecular Medicine Program, University of Utah</institution></institution-wrap><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01tqqny90</institution-id><institution>Department of International Tourism, Nagasaki International University</institution></institution-wrap><addr-line><named-content content-type="city">Nagasaki</named-content></addr-line><country>Japan</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r0ha626</institution-id><institution>Department of Physical Therapy &amp; Athletic Training, University of Utah</institution></institution-wrap><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/037mh3841</institution-id><institution>Sciex</institution></institution-wrap><addr-line><named-content content-type="city">Framingham</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r0ha626</institution-id><institution>Department of Nutrition &amp; Integrative Physiology, University of Utah</institution></institution-wrap><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r0ha626</institution-id><institution>Metabolomics Core Research Facility, University of Utah</institution></institution-wrap><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036jqmy94</institution-id><institution>Fraternal Order of Eagles Diabetes Research Center, University of Iowa</institution></institution-wrap><addr-line><named-content content-type="city">Iowa City</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02f6dcw23</institution-id><institution>Department of Cell Systems and Anatomy, The University of Texas Health Science Center at San Antonio</institution></institution-wrap><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r0ha626</institution-id><institution>Department of Biochemistry, University of Utah</institution></institution-wrap><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Cardozo</surname><given-names>Christopher</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Isales</surname><given-names>Carlos</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012mef835</institution-id><institution>Augusta University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>23</day><month>03</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e85289</elocation-id><history><date date-type="received" iso-8601-date="2022-12-01"><day>01</day><month>12</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-03-22"><day>22</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-12-20"><day>20</day><month>12</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.12.17.473200"/></event></pub-history><permissions><copyright-statement>© 2023, Eshima, Shahtout et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Eshima, Shahtout et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-85289-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-85289-figures-v2.pdf"/><abstract><p>Reactive oxygen species (ROS) accumulation is a cardinal feature of skeletal muscle atrophy. ROS refers to a collection of radical molecules whose cellular signals are vast, and it is unclear which downstream consequences of ROS are responsible for the loss of muscle mass and strength. Here, we show that lipid hydroperoxides (LOOH) are increased with age and disuse, and the accumulation of LOOH by deletion of glutathione peroxidase 4 (GPx4) is sufficient to augment muscle atrophy. LOOH promoted atrophy in a lysosomal-dependent, proteasomal-independent manner. In young and old mice, genetic and pharmacological neutralization of LOOH or their secondary reactive lipid aldehydes robustly prevented muscle atrophy and weakness, indicating that LOOH-derived carbonyl stress mediates age- and disuse-induced muscle dysfunction. Our findings provide novel insights for the role of LOOH in sarcopenia including a therapeutic implication by pharmacological suppression.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>skeletal muscle</kwd><kwd>lipid peroxidation</kwd><kwd>oxidative stress</kwd><kwd>sarcopenia</kwd><kwd>muscle atrophy</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>DK107397</award-id><principal-award-recipient><name><surname>Funai</surname><given-names>Katsuhiko</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>DK127979</award-id><principal-award-recipient><name><surname>Funai</surname><given-names>Katsuhiko</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>GM144613</award-id><principal-award-recipient><name><surname>Funai</surname><given-names>Katsuhiko</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AG074535</award-id><principal-award-recipient><name><surname>Funai</surname><given-names>Katsuhiko</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AG063077</award-id><principal-award-recipient><name><surname>Funai</surname><given-names>Katsuhiko</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AG050781</award-id><principal-award-recipient><name><surname>Drummond</surname><given-names>Micah J</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL122863</award-id><principal-award-recipient><name><surname>Anderson</surname><given-names>Ethan J</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AG057006</award-id><principal-award-recipient><name><surname>Anderson</surname><given-names>Ethan J</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AG064078</award-id><principal-award-recipient><name><surname>Ran</surname><given-names>Qitao</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL149870</award-id><principal-award-recipient><name><surname>Boudina</surname><given-names>Sihem</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL139451</award-id><principal-award-recipient><name><surname>Mahmassani</surname><given-names>Ziad S</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>DK130555</award-id><principal-award-recipient><name><surname>Peterlin</surname><given-names>Alek D</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AG073493</award-id><principal-award-recipient><name><surname>Petrocelli</surname><given-names>Jonathan J</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>915674</award-id><principal-award-recipient><name><surname>Siripoksup</surname><given-names>Piyarat</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>18PRE33960491</award-id><principal-award-recipient><name><surname>Verkerke</surname><given-names>Anthony RP</given-names></name></principal-award-recipient></award-group><award-group id="fund16"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>19PRE34380991</award-id><principal-award-recipient><name><surname>Johnson</surname><given-names>Jordan M</given-names></name></principal-award-recipient></award-group><award-group id="fund17"><funding-source><institution-wrap><institution>Larry H. &amp; Gail Miller Family Foundation</institution></institution-wrap></funding-source><award-id>Predoctoral fellowship</award-id><principal-award-recipient><name><surname>Ferrara</surname><given-names>Patrick J</given-names></name></principal-award-recipient></award-group><award-group id="fund18"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100020320</institution-id><institution>University of Utah Center on Aging</institution></institution-wrap></funding-source><award-id>Pilot grant</award-id><principal-award-recipient><name><surname>Funai</surname><given-names>Katsuhiko</given-names></name></principal-award-recipient></award-group><award-group id="fund19"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008732</institution-id><institution>Uehara Memorial Foundation</institution></institution-wrap></funding-source><award-id>Postdoctoral fellowship</award-id><principal-award-recipient><name><surname>Eshima</surname><given-names>Hiroaki</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Genetic or pharmacological suppression of lipid peroxidation pathway protects skeletal muscle from disuse-induced atrophy and weakness in young and old mice.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Loss of muscle mass and function with age is detrimental to health and quality of life (<xref ref-type="bibr" rid="bib17">Evans, 2010</xref>; <xref ref-type="bibr" rid="bib30">Larsson et al., 2019</xref>). Sarcopenia, muscle atrophy and weakness with aging, is due to a combination of inactivity, injury, surgery, and biological consequences of aging (<xref ref-type="bibr" rid="bib5">Bonaldo and Sandri, 2013</xref>; <xref ref-type="bibr" rid="bib15">Dolbow and Gorgey, 2016</xref>). A pharmacological therapy for muscle loss does not exist, and current diet or exercise therapeutic approaches are often ineffective or unfeasible. Oxidative stress has been implicated in muscle atrophy by accelerating proteolysis (<xref ref-type="bibr" rid="bib36">Powers et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Scicchitano et al., 2018</xref>), but the exact mechanism by which reactive oxygen species (ROS) contributes to the decrease in muscle mass and strength is not well understood.</p><p>Lipid hydroperoxide (LOOH) is a class of ROS molecules that has been implicated in cell damage, particularly as a trigger to induce ferroptosis, a non-apoptotic form of regulated cell death (<xref ref-type="bibr" rid="bib42">Wiernicki et al., 2020</xref>; <xref ref-type="bibr" rid="bib43">Yang et al., 2014</xref>). Lipid peroxidation is initiated by prooxidants such as hydroxyl radicals attacking the carbon-carbon double bond in fatty acids, particularly the polyunsaturated fatty acids (PUFAs) containing phospholipids (<xref ref-type="bibr" rid="bib3">Bochkov et al., 2010</xref>). Lipid radicals (L•) created by this reaction rapidly react with oxygen to form a lipid peroxy-radical which subsequently reacts with another lipid to produce L• and LOOH, the former propagating lipid peroxidation. LOOH is the primary product of lipid peroxidation that forms secondary reactive lipid aldehydes such as 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA), inducing carbonyl stress with high reactivity against biological molecules to promote cellular toxicity. The intracellular level of LOOH is endogenously suppressed by glutathione peroxidase 4 (GPx4) that catalyzes the reaction by which LOOH is reduced to its nonreactive hydroxyl metabolite (<xref ref-type="bibr" rid="bib1">Anderson et al., 2018</xref>).</p><p>Despite the evidence for the role of LOOH-mediated cell damage and cell death, the biological consequence of LOOH accumulation in skeletal muscle is not well understood (<xref ref-type="bibr" rid="bib2">Bhattacharya et al., 2009</xref>; <xref ref-type="bibr" rid="bib35">Pharaoh et al., 2020</xref>). Below, we provide evidence that LOOH mediates loss of muscle mass and function associated with sarcopenia. An increase in muscle LOOH was a common feature with aging and disuse, and accumulation of LOOH in vitro and in vivo augmented muscle atrophy. We further show that genetic or pharmacological suppression of LOOH and their reactive lipid aldehydes is sufficient to prevent disuse-induced muscle atrophy, and to a greater extent in muscle contractile function, in young and old mice.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>We first evaluated the changes in skeletal muscle LOOH with aging. In humans and in mice, aging promoted a reduction in the expression of <italic>Gpx4</italic> in skeletal muscle (<xref ref-type="fig" rid="fig1">Figure 1A, B</xref>). To examine the changes in skeletal muscle LOOH landscape with age, we performed a comprehensive oxidolipidomic analysis in gastrocnemius muscle samples from young (4 months) and old (20 months) mice (<xref ref-type="fig" rid="fig1">Figure 1C, D</xref>). We detected over 300 species of oxidized lipids with an effect distribution that was highly class-dependent. Among these, age had the most robust effect on oxidized phosphatidylethanolamine (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, red), a class of lipids that have been implicated as a potential lipid signal to induce ferroptosis (<xref ref-type="bibr" rid="bib28">Kagan et al., 2017</xref>). Among the top ten oxidized lipid species whose abundance had the most robust fold-increase with age, six of them were oxidized phosphatidylethanolamine species (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). These oxidized phosphatidylethanolamine species were also substantially more highly abundant compared to other oxidized lipids. LOOH can be indirectly assessed by quantifying lipid aldehyde adducts such as 4-HNE and MDA. We confirmed increased muscle 4-HNE and MDA with age (<xref ref-type="fig" rid="fig1">Figure 1E–G</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Lipid hydroperoxides (LOOH) increases with age in skeletal muscle.</title><p>(<bold>A, B</bold>) Glutathione peroxidase 4 (<italic>Gpx4</italic>) mRNA levels in skeletal muscle biopsy samples from young and old humans (n<italic>=</italic>9 young [2 men and 7 women], n<italic>=</italic>18 for old [11 men and 7 women]) (<bold>A</bold>) or gastrocnemius muscles from young and old mice [n<italic>=</italic>8 for young, n<italic>=</italic>7 for old] (<bold>B</bold>). (<bold>C, D</bold>) Oxidized phospholipid content in gastrocnemius muscles from young and old male mice (n<italic>=</italic>8 per group). (<bold>E, F, G</bold>) Immunoblotting (<bold>E</bold>) and quantification (<bold>F</bold>) of 4-hydroxynonenal (4-HNE) proteins (n<italic>=</italic>5 per group) and malondialdehyde (MDA) levels (<bold>G</bold>) (n<italic>=</italic>3 per group) in gastrocnemius muscles. Male mice were used. Data are shown as the mean ± SEM. Statistical analyses in (<bold>A, B, C, D, F</bold>) and (<bold>G</bold>) were performed with an unpaired two-tailed t-test.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Original western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Disuse promotes lipid hydroperoxides (LOOH) in skeletal muscle.</title><p>(<bold>A, B, C</bold>) Body mass (<bold>A</bold>), body composition (<bold>B</bold>), food intake (<bold>C</bold>), following 1 and 7 days of hindlimb unloading (HU) from young wildtype (WT) C57BL/6J mice (n<italic>=</italic>4 for sham, n<italic>=</italic>6 for 1-day HU, n<italic>=</italic>6 for 7-day HU). (<bold>D, E</bold>) Soleus muscle mass (<bold>D</bold>), force-frequency curve (<bold>E</bold>) in soleus muscle following 1 and 7 days of HU from young WT C57BL/6J mice (n<italic>=</italic>4 for sham, n<italic>=</italic>6 for 1-day HU, n<italic>=</italic>6 for 7-day HU). (<bold>F, G</bold>) Immunoblotting (<bold>F</bold>) and quantification (<bold>G</bold>) of 4-hydroxynonenal (4-HNE) in gastrocnemius muscles following 1 and 7 days of HU (n<italic>=</italic>3 per group). (<bold>H</bold>) Rates of oxygen consumption measured in mitochondria (gastrocnemius muscle) with Krebs cycle substrates (n<italic>=</italic>4 for sham, n<italic>=</italic>6 for 1-day HU, n<italic>=</italic>6 for 7-day HU). ADP, adenosine diphosphate; FCCP, carbonyl cyanide-<italic>p</italic>-trifluoromethoxyphenylhydrazone; Mal, malate; Pyr, pyruvate. (<bold>I</bold>) Rate of mitochondrial H<sub>2</sub>O<sub>2</sub> production in response to succinate or Aurorafin/BCNU (n<italic>=</italic>4 for sham, n<italic>=</italic>5 for 1day HU, n<italic>=</italic>5 for 7-day HU). BCNU, 1,3-bis[2-chloroethyl]-1-nitrosourea. (<bold>J</bold>) Percentage of electron leak in muscle mitochondria (n<italic>=</italic>4 for sham, n<italic>=</italic>5 for 1-day HU, n<italic>=</italic>5 for 7-day HU). Data from HU experiments are from female mice. Data are shown as the mean ± SEM. Statistical analyses in (<bold>A, B, C, D, G</bold>) and (<bold>J</bold>) were performed with a one-way analysis of variance (ANOVA) and Dunnett’s multiple comparisons tests. Statistical analyses in (<bold>E, H</bold>) and (<bold>I</bold>) were performed with a two-way ANOVA and Tukey’s multiple comparison test.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Original western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig1-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig1-figsupp1-v2.tif"/></fig></fig-group><p>Disuse promoted by inactivity, injury, or surgery is a major contributor to age-associated decline in muscle mass and function. Disuse also promotes skeletal muscle atrophy that is likely contributed by ROS (<xref ref-type="bibr" rid="bib36">Powers et al., 2011</xref>). To model disuse atrophy, mice underwent a hindlimb unloading (HU) procedure as previously described (<xref ref-type="bibr" rid="bib16">Eshima et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Heden et al., 2019</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–J</xref>). As expected, HU-induced muscle atrophy and weakness (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D, E</xref>) concomitant to reduction in body and lean mass (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B, C</xref>). Disuse robustly elevated muscle LOOH levels (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F, G</xref>) without significant changes in mitochondrial ROS production (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1H-J</xref>). An increase in muscle LOOH preceded atrophy (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D, F</xref>), consistent with the notion that LOOH may trigger mechanisms to promote loss of muscle mass.</p><p>Next, we tested our hypothesis that LOOH contributes to muscle atrophy using C2C12 myotubes (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Lentivirus-mediated knockdown (KD) of GPx4 increased LOOH and markers of ferroptosis concomitant with a decrease in myotube diameter (<xref ref-type="fig" rid="fig2">Figure 2B–I</xref>). We also recapitulated these findings with erastin (a system X<sub>c</sub><sup>-</sup> inhibitor that suppresses glutathione synthesis) (<xref ref-type="fig" rid="fig2">Figure 2B, C</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–E</xref>) and RSL3 (GPx4 inhibitor) (<xref ref-type="fig" rid="fig2">Figure 2B, C</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F–I</xref>), commonly used acute pharmacological interventions to elevate intracellular LOOH. These data support the idea that LOOH reduces myotube size in a cell-autonomous manner.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Elevated lipid hydroperoxides (LOOH) is sufficient to promote atrophy in cultured myotubes.</title><p>(<bold>A</bold>) A schematic of how pathways that regulate LOOH may promote muscle atrophy. PUFA: phospholipids containing polyunsaturated fatty acids. (<bold>B, C</bold>) Representative images (<bold>B</bold>) and quantification (<bold>C</bold>) of myotube diameter (n<italic>=</italic>104 for scrambled: SC, n<italic>=</italic>107 for glutathione peroxidase 4 [GPx4] knockdown [KD], n<italic>=</italic>117 for vehicle, n<italic>=</italic>120 for erastin, n<italic>=</italic>104 for vehicle, n<italic>=</italic>110 for RSL3). Scale bar, 100 μm. (<bold>D</bold>) <italic>Gpx4</italic> mRNA levels in C2C12 myotubes with or without GPx4 knockdown (GPx4 KD) (n<italic>=</italic>6 per group). (<bold>E, F, G</bold>) Immunoblotting of 4-hydroxynonenal (4-HNE), GPx4, and actin (<bold>E</bold>), quantification of 4-HNE (<bold>F</bold>) proteins and malondialdehyde (MDA) levels (<bold>G</bold>) (n<italic>=</italic>3 per group). (<bold>H</bold>) mRNA levels for <italic>Chac1</italic> and <italic>Ptgs2</italic>, markers of ferroptosis (n<italic>=</italic>6 per group). (<bold>I</bold>) Cell death levels in GPx4 KD myoblast or myotubes (n<italic>=</italic>3 independent repeats). Data are shown as the mean ± SEM. Statistical analyses in (<bold>C, D, F, G</bold>) and (<bold>I</bold>) were performed with an unpaired two-tailed t-test. Statistical analyses in (<bold>H</bold>) were performed with a two-way analysis of variance (ANOVA) and Tukey’s multiple comparison test.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Elevated lipid hydroperoxides (LOOH) is sufficient to promote atrophy in cultured myotubes.</title><p>(<bold>A, B, C, D, E</bold>) Quantification of 4-hydroxynonenal (4-HNE) (n<italic>=</italic>2 per group) (<bold>A</bold>), immunoblotting of 4-HNE (<bold>B</bold>) proteins, malondialdehyde (MDA) levels (<bold>C</bold>), mRNA levels for <italic>Chac1</italic> and <italic>Ptgs2</italic>, markers of ferroptosis (<bold>D</bold>), and cell death levels (<bold>E</bold>) in erastin-stimulated C2C12 myotubes (n<italic>=</italic>3 independent repeats). (<bold>F, G, H, I</bold>) mRNA levels of glutathione peroxidase 4 (<italic>Gpx4</italic>) (<bold>F</bold>), immunoblotting of GPx4 and actin (<bold>G</bold>), quantification of GPx4 (n<italic>=</italic>4 per group) (<bold>H</bold>), <italic>Chac1</italic> and <italic>Ptgs2</italic>, markers of ferroptosis (<bold>I</bold>) in RSL3-stimulated C2C12 myotubes (n<italic>=</italic>6 per group). Data are shown as the mean ± SEM. Statistical analyses in (<bold>C, D, E, F, H, I</bold>) and were performed with an unpaired two-tailed t-test. Statistical analyses in (<bold>A</bold>) were performed with a one-way analysis of variance (ANOVA) and Dunnett’s multiple comparisons tests.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Original western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig2-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig2-figsupp1-v2.tif"/></fig></fig-group><p>We then translated these findings in vivo with global heterozygous GPx4 knockout mice (<italic>Gpx4</italic><sup>+/-</sup>). Germline deletion of GPx4 is embryonically lethal (<xref ref-type="bibr" rid="bib44">Yant et al., 2003</xref>), but <italic>Gpx4</italic><sup>+/-</sup> mice appear normal and do not have an observable muscle phenotype at baseline (<xref ref-type="bibr" rid="bib1">Anderson et al., 2018</xref>; <xref ref-type="bibr" rid="bib29">Katunga et al., 2015</xref>). We studied 4 months (young) and 20 months (old) <italic>Gpx4</italic><sup>+/-</sup> and wildtype littermates with or without HU (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A–D</xref>). In young mice, GPx4 haploinsufficiency augmented the loss in soleus mass induced by HU (<xref ref-type="fig" rid="fig3">Figure 3A</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). However, muscle masses between old <italic>Gpx4</italic><sup>+/-</sup> and wildtype mice were not different. We interpret these findings to mean that disuse in old mice promotes an increase in LOOH that has already reached a maximally effective threshold with age such that GPx4 deletion had no further effect. In support of this, we saw no differences in 4-HNE or MDA levels between old <italic>Gpx4</italic><sup>+/-</sup> and wildtype mice (<xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F, G</xref>). GPx4 haploinsufficiency did not alter force-generating capacity (<xref ref-type="fig" rid="fig3">Figure 3C</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1H–J</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Elevated lipid hydroperoxides (LOOH) is sufficient to augment disuse-induced muscle atrophy in young and old mice.</title><p>(<bold>A</bold>) Soleus muscle mass from young or old wildtype (WT) or <italic>Gpx4</italic><sup>+/-</sup> mice with or without hindlimb unloading (HU) (n<italic>=</italic>8–11 per young group, n<italic>=</italic>4–8 per old mice group). (<bold>B</bold>) Immunoblotting of 4-hydroxynonenal (4-HNE) from gastrocnemius muscles in old WT or <italic>Gpx</italic>4<sup>+/-</sup> mice. (<bold>C</bold>) Force-frequency curve from old WT or <italic>Gpx</italic>4<sup>+/-</sup> mice (n<italic>=</italic>4–7 per group). (<bold>D</bold>) mRNA levels of <italic>Gpx4</italic> from young control or GPx4-MKO mice (n<italic>=</italic>4 per group). (<bold>E, F</bold>) Soleus muscle mass (<bold>E</bold>) (n<italic>=</italic>7–8 per group) or force-frequency curve (<bold>F</bold>) from young control or GPx4-MKO mice (n<italic>=</italic>4–7 per group). (<bold>G</bold>) Immunoblotting of 4-HNE and GPx4 from gastrocnemius muscles in young GPx4-MKO. (<bold>H, I</bold>) Representative images of MHC immunofluorescence (<bold>H</bold>) and muscle fiber cross-sectional area (CSA) by fiber type (<bold>I</bold>) for soleus muscles in young control or GPx4-MKO mice with HU (n<italic>=</italic>4 per group). Scale bar, 100 µm. Data from <italic>Gpx4</italic><sup>+/-</sup> and GPx4-MKO experiments are from male and female mice. Data are shown as the mean ± SEM. Statistical analyses in (<bold>D</bold>) were performed with an unpaired two-tailed t-test. Statistical analyses in (<bold>A, C, E, F</bold>) and (<bold>I</bold>) were performed with a two-way analysis of variance (ANOVA) and multiple comparisons were performed using Tukey’s (<bold>C, E, F, I</bold>) or Sidak’s (<bold>A</bold>) multiple comparisons tests. GPx4, glutathione peroxidase 4.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Original western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig3-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Additional data from <italic>Gpx4</italic><sup>+/-</sup> mice.</title><p>(<bold>A</bold>) Body mass from young and old wildtype (WT) or <italic>Gpx4</italic><sup>+/-</sup> mice. (<bold>B, C</bold>) Body composition from young (n<italic>=</italic>9 for WT sham, n<italic>=</italic>8 for <italic>Gpx4</italic><sup>+/-</sup> sham, n<italic>=</italic>7 for WT hindlimb unloading (HU), n<italic>=</italic>6 for <italic>Gpx4</italic><sup>+/-</sup> HU) (<bold>B</bold>) and old (n<italic>=</italic>4 for WT sham, n<italic>=</italic>5 for <italic>Gpx4</italic><sup>+/-</sup> sham, n<italic>=</italic>8 for WT HU, n<italic>=</italic>6 for <italic>Gpx4</italic><sup>+/-</sup> HU) (<bold>C</bold>) WT or <italic>Gpx4</italic><sup>+/-</sup> mice. (<bold>D</bold>) Food intake during HU in young (n<italic>=</italic>7 for WT, n<italic>=</italic>6 for <italic>Gpx4</italic><sup>+/-</sup>) and old (n<italic>=</italic>8 for WT, n<italic>=</italic>6 for <italic>Gpx4</italic><sup>+/-</sup>) WT or <italic>Gpx4</italic><sup>+/-</sup> mice. (<bold>E</bold>) Extensor digitorum long (EDL) muscle mass from young (n<italic>=</italic>9 for WT sham, n<italic>=</italic>8 for <italic>Gpx4</italic><sup>+/-</sup> sham, n<italic>=</italic>7 for WT HU, n<italic>=</italic>6 for <italic>Gpx4</italic><sup>+/-</sup> HU) and old (n<italic>=</italic>9 for WT sham, n<italic>=</italic>8 for <italic>Gpx4</italic><sup>+/-</sup> sham, n<italic>=</italic>7 for WT HU, n<italic>=</italic>6 for <italic>Gpx4</italic><sup>+/-</sup> HU) WT or <italic>Gpx4</italic><sup>+/-</sup> mice. (<bold>F</bold>) Quantification of 4-hydroxynonenal (4-HNE) from gastrocnemius muscles in old mice (n<italic>=</italic>3 per group). (<bold>G</bold>) Malondialdehyde (MDA) levels from gastrocnemius muscles in old mice (n<italic>=</italic>3 per group). (<bold>H</bold>) Force-frequency curve from soleus muscle from young WT or <italic>Gpx4</italic><sup>+/-</sup> mice (n<italic>=</italic>5 for WT sham, n<italic>=</italic>5 for <italic>Gpx4</italic><sup>+/-</sup> sham, n<italic>=</italic>7 for WT HU, n<italic>=</italic>5 for <italic>Gpx4</italic><sup>+/-</sup> HU). (<bold>I,J</bold>) Force-frequency curve in EDL muscle from young (n<italic>=</italic>5 for WT sham, n<italic>=</italic>5 for <italic>Gpx4</italic><sup>+/-</sup> sham, n<italic>=</italic>7 for WT HU, n<italic>=</italic>5 for <italic>Gpx4</italic><sup>+/-</sup> HU) (<bold>I</bold>) and old (n<italic>=</italic>3 for WT sham, n<italic>=</italic>4 for <italic>Gpx4</italic><sup>+/-</sup> sham, n<italic>=</italic>6 for WT HU, n<italic>=</italic>6 for <italic>Gpx4</italic><sup>+/-</sup> HU) (<bold>J</bold>) WT or <italic>Gpx4</italic><sup>+/-</sup> mice. Data from <italic>Gpx4</italic><sup>+/-</sup> experiments are from male and female mice. Data are shown as the mean ± SEM. Statistical analyses in (<bold>A, B, C, D, E, F, G, H, I, J</bold>) were performed with a two-way analysis of variance (ANOVA) and using Tukey’s multiple comparisons tests. GPx4, glutathione peroxidase 4.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Additional data from GPx4-MKO mice.</title><p>(<bold>A</bold>) Genotyping gel for GPx4cKO<sup>lox/lox</sup> mice crossed with HSA-MerCreMer<sup>+/-</sup> mice to yield GPx4cKO<sup>lox/lox</sup>; HSA-MerCreMer<sup>+/-</sup> (GPx4-MKO) mice. Control littermates (GPx4cKO<sup>lox/lox</sup>; HSA-MerCreMer<sup>-/-</sup>) were used for experiments. (<bold>B, C</bold>) Body mass (<bold>B</bold>) and body composition (<bold>C</bold>) (n<italic>=</italic>7 for Ctrl sham, n<italic>=</italic>4 for GPx4-MKO sham, n<italic>=</italic>7 for Ctrl hindlimb unloading (HU), n<italic>=</italic>8 for GPx4-MKO HU). (<bold>D</bold>) Food intake during HU (n<italic>=</italic>7 for Ctrl, n<italic>=</italic>8 for GPx4-MKO). (<bold>E, F</bold>) Extensor digitorum long (EDL) muscle mass (n<italic>=</italic>6 for Ctrl sham, n<italic>=</italic>4 for GPx4-MKO sham, n<italic>=</italic>7 for Ctrl HU, n<italic>=</italic>8 for GPx4-MKO HU) (<bold>E</bold>) and force-frequency curve from young mice (n<italic>=</italic>6 for Ctrl sham, n<italic>=</italic>4 for GPx4-MKO sham, n<italic>=</italic>6 for Ctrl HU, n<italic>=</italic>7 for GPx4-MKO HU) (<bold>F</bold>). (<bold>G</bold>) Quantification of western blotting for 4-hydroxynonenal (4-HNE) from gastrocnemius muscles in young mice (n<italic>=</italic>3 per group). (<bold>H</bold>) mRNA levels of <italic>Chac1</italic> and <italic>Ptgs2</italic> in gastrocnemius muscles (n<italic>=</italic>4 per group). (<bold>I, J</bold>) Mean muscle fiber cross-sectional area (CSA) (<bold>I</bold>) and fiber-type composition (<bold>J</bold>) for soleus muscles following HU (n<italic>=</italic>4 per group). Data from GPx4-MKO experiments are from male and female mice. Data are shown as the mean ± SEM. Statistical analyses in (<bold>D</bold>) and (<bold>I</bold>) were performed with an unpaired two-tailed t-test. Statistical analyses in (<bold>B, C, E, F, G, H</bold>) and (<bold>J</bold>) were performed with a two-way analysis of variance (ANOVA) and Tukey’s multiple comparison test.</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Original genotyping gels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig3-figsupp2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig3-figsupp2-v2.tif"/></fig></fig-group><p>Because GPx4 is expressed globally, we also studied mice with skeletal muscle-specific tamoxifen-inducible GPx4 knockout (GPx4-MKO) (<xref ref-type="fig" rid="fig3">Figure 3D</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>; <xref ref-type="bibr" rid="bib45">Yoo et al., 2012</xref>). Consistent with <italic>Gpx4</italic><sup>+/-</sup> mice, soleus muscles from GPx4-MKO mice were also more prone to developing disuse-induced atrophy (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B–F</xref>) concomitant to elevated LOOH (<xref ref-type="fig" rid="fig3">Figure 3G</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2G, H</xref>), suggesting that loss of GPx4 in muscle augments atrophy in a cell-autonomous manner. Histological analyses revealed that reduced muscle mass was consistent with reduced cross-sectional area (CSA) of myofibers regardless of fiber-type compositions (<xref ref-type="fig" rid="fig3">Figure 3H&amp;I</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2I, J</xref>). These data implicate that LOOH directly reduces muscle cell size in vivo.</p><p>GPx4 primarily neutralizes LOOH but it also exhibits some activity toward other peroxides (<xref ref-type="bibr" rid="bib26">Imai and Nakagawa, 2003</xref>). To confirm that the effects of GPx4 deletion to promote atrophy is specific to LOOH, we diminished the ability of cells to incorporate PUFAs into phospholipids by deleting lysophosphatidylcholine acyltransferase 3 (LPCAT3) (<xref ref-type="bibr" rid="bib31">Lee et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Ferrara et al., 2021a</xref>; <xref ref-type="bibr" rid="bib21">Ferrara et al., 2021b</xref>). LPCAT3 is an enzyme of Lands cycle that preferentially acylates lysophospholipids with PUFAs, and thus an essential component of ferroptosis (<xref ref-type="bibr" rid="bib28">Kagan et al., 2017</xref>). Indeed, LPCAT3 KD rescued the increase in 4-HNE induced by GPx4 KD (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Remarkably, deletion of LPCAT3 KD completely restored the reduction in myotube diameter induced by GPx4 KD (<xref ref-type="fig" rid="fig4">Figure 4D&amp;E</xref>). Similarly, LPCAT3 deletion also prevented LOOH and cell death induced by erastin (<xref ref-type="fig" rid="fig4">Figure 4F–H</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B, C</xref>). These findings indicate that muscle atrophy induced by loss of GPx4 or erastin treatment is due to the accumulation of LOOH and not other peroxides.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Suppression of polyunsaturated fatty acid (PUFA) incorporation prevents lipid hydroperoxides (LOOH)-induced myotube atrophy.</title><p>(<bold>A</bold>) mRNA levels of lysophosphatidylcholine acyltransferase 3 (<italic>Lpcat3</italic>) in C2C12 myotubes with or without LPCAT3 knockdown (KD) (n<italic>=</italic>3 per group). (<bold>B</bold>) Immunoblotting of 4-hydroxynonenal (4-HNE), glutathione peroxidase 4 (GPx4), and actin protein in C2C12 myotubes with or without GPx4 KD and/or LPCAT3 KD. (<bold>C</bold>) Quantification of 4-HNE proteins in C2C12 myotubes with or without LPCAT3 KD and/or GPx4 KD (n=3 per group). (<bold>D, E</bold>) Representative images (<bold>D</bold>), and quantification of myotube diameter (<bold>E</bold>) from C2C12 myotubes with or without GPx4 KD and/or without LPCAT3 KD (n<italic>=</italic>104–114 per group). Scale bar, 100 μm. (<bold>F, G</bold>) Immunoblotting (<bold>F</bold>) and quantification (<bold>G</bold>) of 4-HNE from C2C12 myotubes with or without LPCAT 3 KD and/or erastin (n<italic>=</italic>3 per group). (<bold>H</bold>) Representative images from C2C12 myotubes with or without LPCAT3 KD and/or erastin (n<italic>=</italic>3 independent repeats). Scale bar, 100 μm. Data are shown as the mean ± SEM. Statistical analyses in (<bold>A</bold>) were performed with an unpaired two-tailed t-test. Statistical analysis in (<bold>C</bold>) and (<bold>G</bold>) were performed with a two-way analysis of variance (ANOVA) and multiple comparisons were performed using Tukey’s multiple comparisons tests. Statistical analyses in (<bold>E</bold>) was performed with a one-way ANOVA with Dunnett’s multiple comparisons test.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig4-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Additional data from lysophosphatidylcholine acyltransferase 3 (LPCAT3) knockdown (KD).</title><p>(<bold>A</bold>) mRNA levels of glutathione peroxidase 4 (<italic>Gpx4</italic>) and <italic>Lpcat3</italic> in C2C12 myotubes with or without GPx4 and LPCAT3 double KD (n<italic>=</italic>3 per group). (<bold>B</bold>) mRNA levels of <italic>Lpcat3</italic> from erastin-stimulated myotubes (n<italic>=</italic>3 per group). (<bold>C</bold>) Cell death levels from C2C12 myotubes with or without LPCAT3 KD and/or erastin (n<italic>=</italic>3 independent repeats). Data are shown as the mean ± SEM. Statistical analyses in (<bold>A</bold>) and (<bold>B</bold>) were performed with an unpaired two-tailed t-test. Statistical analyses in (<bold>C</bold>) were performed with a two-way analysis of variance (ANOVA) and Tukey’s multiple comparison test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig4-figsupp1-v2.tif"/></fig></fig-group><p>What is the mechanism by which LOOH promotes muscle atrophy? C2C12 myotubes were pretreated with bafilomycin A1 (BafA1) or MG132 prior to erastin incubation to determine whether LOOH increases protein degradation in a lysosomal- or proteasomal-dependent manner, respectively. Erastin-induced reduction in myotube diameter was suppressed with BafA1, but not with MG132 (<xref ref-type="fig" rid="fig5">Figure 5A, B</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>), suggesting that the lysosome mediates protein degradation by LOOH (<xref ref-type="bibr" rid="bib23">Gao et al., 2018</xref>). We also reproduced these findings with RSL3 treatment (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B, C</xref>). How does LOOH, a lipid molecule, promote lysosomal degradation? Upstream of the lysosome, autophagosome formation is mediated by a lipidation of LC3 by ATG3 (<xref ref-type="bibr" rid="bib25">Ichimura et al., 2000</xref>). Thus, we hypothesized that LOOH may affect the lipidation of LC3. Indeed, GPx4 KD drastically reduced the protein content of p62, LC3-I, and LC3-II (<xref ref-type="fig" rid="fig5">Figure 5C</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D–H</xref>), potentially suggesting that LOOH either accelerates lysosomal degradation or reduces synthesis of these proteins. To test this possibility, we performed a targeted deletion of ATG3 in vitro. Indeed, ATG3 KD completely rescued the reduction in myotube diameter induced by GPx4 KD (<xref ref-type="fig" rid="fig5">Figure 5D, E</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1I–L</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Suppression of the autophagy-lysosome axis prevents lipid hydroperoxides (LOOH)-induced myotube atrophy.</title><p>(<bold>A, B</bold>) Representative images (<bold>A</bold>), and quantification of myotube diameter (<bold>B</bold>) from erastin-stimulated C2C12 myotubes with proteasomal inhibitor MG132 or lysosomal inhibitor bafilomycin A1 (BaFA1) (n<italic>=</italic>21–120 per group). Scale bar, 100 µm. (<bold>C</bold>) Autophagic flux analyses immunoblotting for LC3-I, LC3-II, p62, and actin in SC or glutathione peroxidase 4 (GPx4) knockdown (KD) C2C12 myotubes with or without BafA1. (<bold>D, E</bold>) Representative images (<bold>D</bold>) and quantification of myotube diameter (<bold>E</bold>) from C2C12 myotubes with or without GPx4 KD and/or ATG3 KD (n<italic>=</italic>104–121 per group). Data are shown as the mean ± SEM. Statistical analyses in (<bold>B, E</bold>) were performed with a one-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Original western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig5-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>The autophagy-lysosome axis in lipid hydroperoxides (LOOH)-induced myotube atrophy.</title><p>(<bold>A</bold>) Cell death levels in erastin-stimulated myotubes with MG132 or bafilomycin A1 (BaFA1) (n<italic>=</italic>3 independent repeats). (<bold>B, C</bold>) Representative images (<bold>B</bold>) and cell death level (<bold>C</bold>) in RSL3-stimulated myotubes with BaFA1 (n<italic>=</italic>3 independent repeats). (<bold>D,E</bold>) Immunoblotting (<bold>D</bold>) and quantification (<bold>E</bold>) of LC3-I, LC3-II, p62 (all static measurements without BafA1), and actin protein from C2C12 myotubes with or without GPX4 knockdown (KD) (n<italic>=</italic>4 per group). (<bold>F, G, H</bold>) Quantification of western blotting for LC3-I (<bold>F</bold>), LC3-II (<bold>G</bold>), and p62 (<bold>H</bold>) protein from GPx4 KD myotubes with or without BaFA1 (n<italic>=</italic>3 per group). (<bold>I</bold>) mRNA levels of <italic>Atg3</italic> in C2C12 myotubes with or without (n<italic>=</italic>3 per group). (<bold>J</bold>) mRNA levels of <italic>Gpx4</italic> and ATG3 from C2C12 myotubes with double KD for ATG3 and GPx4 (n<italic>=</italic>3 per group). (<bold>K, L</bold>) Immunoblotting (<bold>K</bold>) and quantification (<bold>L</bold>) of LC3, p62, and GPx4 protein from C2C12 myotubes with or without ATG3 KD (n<italic>=</italic>3 per group). Data are shown as the mean ± SEM. Statistical analyses in (<bold>C, I</bold>) and (<bold>L</bold>) were performed with an unpaired two-tailed t-test. Statistical analyses in (<bold>A</bold>) were performed with a one-way analysis of variance (ANOVA) and Tukey’s multiple comparison test. Statistical analyses in (<bold>E, F, G, H, I</bold>) and (<bold>J</bold>) were performed with a two-way ANOVA and Tukey’s multiple comparison test.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Original western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig5-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Leveraging these findings, we generated mice with skeletal muscle-specific tamoxifen-inducible ATG3 knockout (ATG3-MKO) (<xref ref-type="fig" rid="fig6">Figure 6A, B</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>) and studied them with or without HU (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B–E</xref>). Loss of ATG3 was protective from disuse-induced atrophy (<xref ref-type="fig" rid="fig6">Figure 6C</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>) in soleus and weakness (<xref ref-type="fig" rid="fig6">Figure 6D</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1G</xref>) in soleus and EDL. The protective effect of muscle mass in soleus was likely explained by greater myofiber CSA (<xref ref-type="fig" rid="fig6">Figure 6E, F</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1H</xref>). Thus, suppression of autophagy is sufficient to attenuate disuse-induced muscle atrophy and weakness.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Muscle-specific ATG3 deletion attenuates disuse-induced atrophy and weakness.</title><p>(<bold>A</bold>) mRNA levels of <italic>Atg3</italic> (n<italic>=</italic>8–32 per group) from young control or ATG3-MKO mice. (<bold>B</bold>) Immunoblotting of p62, LC3, and GAPDH proteins from gastrocnemius muscles from control and ATG3-MKO mice. (<bold>C</bold>) Soleus muscle mass from control or ATG3-MKO mice (n<italic>=</italic>10–12 per group). (<bold>D</bold>) Force-frequency curve from young control or ATG3-MKO mice (n<italic>=</italic>9–12 per group). (<bold>E, F</bold>) Representative images of MHC immunofluorescence (<bold>E</bold>) and muscle fiber cross-sectional area (CSA) by fiber type (<bold>F</bold>) of soleus muscles in young control or ATG3-MKO mice with hindlimb unloading (HU) (n<italic>=</italic>6 per group). Data from ATG3-MKO experiments are from female mice. Data are shown as the mean ± SEM. Statistical analyses in (<bold>A</bold>) were performed with an unpaired two-tailed t-test. Statistical analyses in (<bold>C, D</bold>) and (<bold>F</bold>) were performed with a two-way analysis of variance (ANOVA) and multiple comparisons were performed using Tukey’s multiple comparisons tests.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Original western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig6-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Additional data from ATG3-MKO mice.</title><p>(<bold>A</bold>) Genotyping of ATG3cKO<sup>lox/lox</sup> mice crossed with HSA-MerCreMer<sup>+/-</sup> mice to yield ATG3cKO<sup>lox/lox</sup>; HSA-MerCreMer<sup>+/-</sup> (ATG3-MKO) mice. Control littermates (ATG3cKO<sup>lox/lox</sup>; HSA-MerCreMer<sup>-/-</sup>) were used for experiments. (<bold>B</bold>) Quantification of LC3-II/I ratio in muscles from control and ATG3-MKO mice (n<italic>=</italic>8 per group). (<bold>B, C, D</bold>) Body weight (<bold>B</bold>), lean mass (<bold>C</bold>), and fat mass (<bold>D</bold>) from control and ATG3-MKO mice (control sham n<italic>=</italic>9, ATG3-MKO sham n<italic>=</italic>10, control hindlimb unloading [HU] n<italic>=</italic>10, ATG3-MKO HU n<italic>=</italic>10). (<bold>E</bold>) Extensor digitorum long (EDL) muscle mass (control sham n<italic>=</italic>10, ATG3-MKO sham n<italic>=</italic>12, control HU n<italic>=</italic>10, ATG3-MKO HU n<italic>=</italic>10). (<bold>F</bold>) Force-frequency curve for EDL muscle (control sham n<italic>=</italic>9, ATG3-MKO sham n<italic>=</italic>8, control HU n<italic>=</italic>10, ATG3-MKO HU n<italic>=</italic>9). (<bold>G</bold>) Fiber-type composition for soleus (SOL) muscle (control HU n<italic>=</italic>6, ATG3MKO HU n<italic>=</italic>6). Data from ATG3-MKO experiments are from female mice. Data are shown as the mean ± SEM. Statistical analyses in (<bold>B, C, D, E, F, G</bold>) were performed with a two-way analysis of variance (ANOVA) and Tukey’s multiple comparison test.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Original genotyping gels and western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig6-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig6-figsupp1-v2.tif"/></fig></fig-group><p>We initially hypothesized that lysosomal degradation mediates LOOH-induced protein degradation to contribute to muscle atrophy. However, further assessment of muscle LOOH illuminated a more complex interaction between the lysosome and LOOH (<xref ref-type="bibr" rid="bib10">Chen et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Gao et al., 2016</xref>). Unexpectedly, quantification of 4-HNE revealed that inhibition of the autophagy-lysosome axis by ATG3 deletion or BafA1 was sufficient to inhibit LOOH induced by GPx4 deletion, erastin, or RSL3 (<xref ref-type="fig" rid="fig7">Figure 7A–D</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A–D</xref>). These findings suggest that the autophagy-lysosome axis is essential for LOOH amplification, in addition to its potential role in mediating protein degradation downstream. Indeed, immunofluorescence experiments revealed that 4-HNE is highly co-localized to LAMP2 (<xref ref-type="fig" rid="fig7">Figure 7E</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1E</xref>), consistent with the notion that the lysosome is necessary for LOOH propagation. To support this idea, an increase in LOOH by hydrogen peroxide or carmustine (agents that increase pan oxidative stress without acting on GPx4 directly) was completely inhibited by lysosomal inhibition (<xref ref-type="fig" rid="fig7">Figure 7F–H</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1F, G</xref>). Together, these observations suggest that the propagation of LOOH may be mediated by the lysosome (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1H</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Inhibition of the autophagy-lysosome axis prevents accumulation of lipid hydroperoxides (LOOH).</title><p>(<bold>A, B</bold>) Immunoblotting (<bold>A</bold>) and quantification (<bold>B</bold>) of 4-hydroxynonenal (4-HNE), glutathione peroxidase 4 (GPx4), and actin in C2C12 myotubes with or without GPx4 knockdown (KD) and/or ATG3 KD (n<italic>=</italic>3 per group). (<bold>C, D</bold>) Immunoblotting (<bold>C</bold>) and quantification (<bold>D</bold>) of 4-HNE protein from C2C12 myotubes with or without erastin and/or bafilomycin A1 (BaFA1) (n<italic>=</italic>3 per group). (<bold>E</bold>) Confocal fluorescence microscope images of erastin-stimulated myotubes with or without BaFA1. Scale bar, 10 µm. Boxed regions are shown enlarged at far right. Scale bar, 2.5 µm. (<bold>F, G, H</bold>) Representative images (<bold>F</bold>), immunoblotting of 4-HNE and actin (<bold>G</bold>), and quantification (<bold>H</bold>) of H<sub>2</sub>O<sub>2</sub> or BCNU-stimulated C2C12 myotubes with or without BaFA1 (n<italic>=</italic>3 per group). Scale bar, 100 µm. Data are shown as the mean ± SEM. Statistical analyses in (<bold>B, D</bold>) and (<bold>H</bold>) were performed with a two-way analysis of variance (ANOVA) and Tukey’s multiple comparison test.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Original western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig7-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Inhibition of the autophagy-lysosome axis prevents accumulation of lipid hydroperoxides (LOOH).</title><p>(<bold>A, B</bold>) Immunoblotting (<bold>A</bold>) and quantification (<bold>B</bold>) of 4-hydroxynonenal (4-HNE) protein from C2C12 myotubes with or without erastin and/or ATG3 knockdown (KD) (n<italic>=</italic>3 per group). (<bold>C, D</bold>) Immunoblotting (<bold>C</bold>) and quantification (<bold>D</bold>) of 4-HNE protein from C2C12 myotubes with or without erastin and/or bafilomycin A1 (BaFA1) (n<italic>=</italic>3 per group). (<bold>E</bold>) Confocal immunofluorescence of LAMP2 (lysosome) and 4-HNE in erastin-stimulated C2C12 myotubes with or without BaFA1. Scale bar, 10 µm. (<bold>F, G</bold>) Immunoblotting (<bold>F</bold>) and quantification (<bold>G</bold>) of 4-HNE protein from BCNU-stimulated C2C12 myotubes with or without BafA1 (n<italic>=</italic>3 per group). (<bold>H</bold>) A novel role of the lysosome in amplifying LOOH. Data are shown as the mean ± SEM. Statistical analyses in (<bold>B, D</bold>) and (<bold>G</bold>) were performed with a two-way analysis of variance (ANOVA) and Tukey’s multiple comparison test.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Original western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig7-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig7-figsupp1-v2.tif"/></fig></fig-group><p>Inhibition of autophagy suppressed lysosomal degradation and LOOH to attenuate muscle atrophy. We next tested whether suppression of LOOH would be sufficient to ameliorate skeletal muscle atrophy. We studied young (4 months) and old (20 months) global GPx4-overexpressing (GPx4Tg) mice (<xref ref-type="bibr" rid="bib37">Ran et al., 2004</xref>) with or without HU (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A–E</xref>). Strikingly, both young and old GPx4Tg mice were resistant to disuse-induced muscle atrophy (<xref ref-type="fig" rid="fig8">Figure 8A</xref> and <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1F, G</xref>, greater effect in soleus than EDL). Perhaps even more impactful was the effect of GPx4 overexpression on skeletal muscle force-generating capacity such that, in both young and old, GPx4 overexpression robustly protected mice from muscle weakness induced by HU (<xref ref-type="fig" rid="fig8">Figure 8B</xref> and <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1H–J</xref>, soleus and EDL). These findings are in contrast to our experiments in <italic>Gpx4</italic><sup>+/-</sup> mice where muscle mass phenotype was only present in the young mice (<xref ref-type="fig" rid="fig3">Figure 3A</xref>) and no phenotype on muscle strength (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Consistent with the notion that GPx4 overexpression acts on LOOH, HU-induced increase in 4-HNE was completely suppressed in GPx4Tg mice (<xref ref-type="fig" rid="fig8">Figure 8C</xref> and <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1K</xref>). We also found that the protection from muscle atrophy was explained by greater myofiber CSA regardless of fiber type (<xref ref-type="fig" rid="fig8">Figure 8D&amp;E</xref> and <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1L, M</xref>).</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Overexpression of glutathione peroxidase 4 (GPx4) ameliorates disuse-induced muscle atrophy and weakness in young and old mice.</title><p>(<bold>A</bold>) Soleus muscle mass from young or old wildtype (WT) or GPx4Tg mice with or without hindlimb unloading (HU) (n<italic>=</italic>6–11 per young group, n<italic>=</italic>7 per old group). (<bold>B</bold>) Force-frequency curve from old WT or GPx4Tg mice (n<italic>=</italic>5–7 per group). (<bold>C</bold>) Immunoblotting of 4-hydroxynonenal (4-HNE) in gastrocnemius muscles from old WT or GPx4Tg mice. (<bold>D, E</bold>) Representative images of MHC immunofluorescence (<bold>D</bold>) and muscle fiber cross-sectional area (CSA) by fiber type (<bold>E</bold>) for soleus muscles in old WT or GPx4Tg mice with HU (n<italic>=</italic>4–6 per group). (<bold>F</bold>) Immunoblotting of 4-HNE, and actin in C2C12 myotubes with or without GPx4 KD and/or ferrostatin-1. (<bold>G, H</bold>) Representative images (<bold>G</bold>), and quantification of myotube diameter (<bold>H</bold>) from C2C12 myotubes with GPx4 KD and/or ferrostatin-1 treatments (n<italic>=</italic>102–110 per group). Scale bar, 100 μm. Data from GPx4Tg experiments are from male and female mice. Data are shown as the mean ± SEM. Statistical analyses in (<bold>H</bold>) was performed with a one-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test, and statistical analyses in (<bold>A, B</bold>) and (<bold>E</bold>) were performed with a two-way ANOVA and were performed using Tukey’s (<bold>B, E</bold>) or Sidak’s (<bold>A</bold>) multiple comparisons tests.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Original western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig8-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Additional data from GPx4Tg mice.</title><p>(<bold>A</bold>) Quantification of GPx4 proteins from wildtype (WT) or GPx4Tg with or without hindlimb unloading (HU) (n<italic>=</italic>3 per group). (<bold>B</bold>) Body mass from young (n<italic>=</italic>9 for WT, n<italic>=</italic>8 for GPx4Tg) and old (n<italic>=</italic>7 for WT, n<italic>=</italic>7 for GPx4Tg) mice. (<bold>C, D</bold>) Body composition from young mice (<bold>C</bold>) and old mice (<bold>D</bold>). (<bold>E</bold>) Food intake during HU from young and old mice. (<bold>F, G</bold>) Extensor digitorum long (EDL) muscle mass from young (n<italic>=</italic>6 for WT sham, n<italic>=</italic>8 for GPx4Tg sham, n<italic>=</italic>9 for WT HU, n<italic>=</italic>8 for GPx4Tg HU) (<bold>F</bold>) and old (n<italic>=</italic>7 per group) (<bold>G</bold>) mice. (<bold>H</bold>) Force-frequency curve in soleus muscle from young mice (n<italic>=</italic>5 for WT sham, n<italic>=</italic>6 for GPx4Tg sham, n<italic>=</italic>9 for WT HU, n<italic>=</italic>8 for GPx4Tg HU). (<bold>I, J</bold>) Force-frequency curve in EDL muscle from young mice (n<italic>=</italic>5 for WT sham, n<italic>=</italic>7 for GPx4Tg sham, n<italic>=</italic>9 for WT HU, n<italic>=</italic>8 for GPx4Tg HU) (<bold>I</bold>) and old (n<italic>=</italic>5 for WT sham, n<italic>=</italic>5 for GPx4Tg sham, n<italic>=</italic>5 for WT HU, n<italic>=</italic>6 for GPx4Tg HU) (<bold>J</bold>) mice. (<bold>K</bold>) Quantification of 4-hydroxynonenal (4-HNE) proteins from gastrocnemius muscles in old mice (n<italic>=</italic>3 per group). (<bold>L, M</bold>) Mean muscle fiber cross-sectional area (CSA) (<bold>L</bold>) and fiber-type composition (<bold>M</bold>) for soleus muscles from old mice following HU (n<italic>=</italic>6 for WT, n<italic>=</italic>4 for GPx4Tg). Data from GPx4Tg experiments are from male and female mice. Data are shown as the mean ± SEM. Statistical analyses in (<bold>L</bold>) were performed with an unpaired two-tailed t-test. Statistical analyses in (<bold>A–M</bold>) were performed with a two-way analysis of variance (ANOVA) and Tukey’s multiple comparison test. GPx4, glutathione peroxidase 4.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig8-figsupp1-v2.tif"/></fig><fig id="fig8s2" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 2.</label><caption><title>Effects of ferrostatin-1 or L-carnosine treatment in vitro.</title><p>(<bold>A, B, C</bold>) Quantification of 4-hydroxynonenal (4-HNE) proteins (n<italic>=</italic>2 per group) (<bold>A</bold>), cell death level (n<italic>=</italic>3 independent repeats) (<bold>B</bold>), and mRNA levels of <italic>Chac1</italic> and <italic>Ptgs2</italic> with or without glutathione peroxidase 4 (GPx4) KD and/or ferrostatin-1 (n<italic>=</italic>6 for SC, n<italic>=</italic>5 for GPx4 KD) (<bold>C</bold>) in C2C12 myotubes. (<bold>D, E, F</bold>) Immunoblotting (<bold>D</bold>) and quantification (<bold>E</bold>) of 4-HNE, and actin (n<italic>=</italic>3 per group) and cell death level (n<italic>=</italic>3 independent repeats) (<bold>F</bold>) with or without erastin and/or L-carnosine in C2C12 myotubes. (<bold>G, H, I</bold>) Immunoblotting (<bold>G</bold>) and quantification (<bold>H</bold>) of 4-HNE and actin (n<italic>=</italic>3 per group), and (<bold>I</bold>) cell death level (n<italic>=</italic>3 independent repeats) in C2C12 myotubes with or without GPx4 KD and/or L-carnosine. Data are shown as the mean ± SEM. Statistical analyses in (<bold>E</bold>) and (<bold>F</bold>) were performed with a one-way analysis of variance (ANOVA) and Tukey’s multiple comparison test. Statistical analyses in (<bold>A, B, C, H</bold>) and (<bold>I</bold>) were performed with a two-way ANOVA and Tukey’s multiple comparison test.</p><p><supplementary-material id="fig8s2sdata1"><label>Figure 8—figure supplement 2—source data 1.</label><caption><title>Original western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig8-figsupp2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig8-figsupp2-v2.tif"/></fig><fig id="fig8s3" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 3.</label><caption><title>L-carnosine treatment partly ameliorates disuse-induced muscle atrophy.</title><p>(<bold>A, B, C, D, E, F, G</bold>) Body mass (<bold>A</bold>), body composition (n<italic>=</italic>6 for vehicle sham, n<italic>=</italic>7 for L-carnosine sham, n<italic>=</italic>12 for vehicle hindlimb unloading [HU], n<italic>=</italic>13 for L-carnosine HU) (<bold>B</bold>), food intake (<bold>C</bold>), water intake (n<italic>=</italic>6 for vehicle sham, n<italic>=</italic>6 for L-carnosine sham, n<italic>=</italic>6 for vehicle HU, n<italic>=</italic>7 for L-carnosine HU) (<bold>D</bold>), immunoblotting (<bold>E</bold>), and quantification (<bold>F</bold>) of 4-hydroxynonenal (4-HNE) in gastrocnemius muscles (n<italic>=</italic>3 per group), and soleus muscle mass (n<italic>=</italic>6 for vehicle sham, n<italic>=</italic>7 for L-carnosine sham, n<italic>=</italic>12 for vehicle HU, n<italic>=</italic>13 for L-carnosine HU) (<bold>G</bold>). Data from L-carnosine experiments are from male mice. Data are shown as the mean ± SEM. Statistical analyses in (<bold>A, B, C, D, F</bold>) and (<bold>G</bold>) were performed with a two-way analysis of variance (ANOVA) and Tukey’s multiple comparison test.</p><p><supplementary-material id="fig8s3sdata1"><label>Figure 8—figure supplement 3—source data 1.</label><caption><title>Original blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig8-figsupp3-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig8-figsupp3-v2.tif"/></fig></fig-group><p>Next, we explored opportunities to pharmacologically suppress LOOH to prevent muscle atrophy. Ferrostatin-1 inhibits the propagation of lipid peroxidation and is widely used to study LOOH (<xref ref-type="bibr" rid="bib14">Dixon et al., 2012</xref>; <xref ref-type="bibr" rid="bib11">Codenotti et al., 2018</xref>). Indeed, incubation of cells with ferrostatin-1 was sufficient to suppress LOOH induced by GPx4 KD (<xref ref-type="fig" rid="fig8">Figure 8F</xref> and <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2A</xref>) concomitant with protection from myotube atrophy (<xref ref-type="fig" rid="fig8">Figure 8G&amp;H</xref> and <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2B, C</xref>). Nevertheless, ferrostatin-1 is currently not an FDA-approved drug with uncertainty surrounding safety. Thus, we tested L-carnosine, a dipeptide composed of beta-alanine and L-histidine that has the ability to scavenge reactive lipid aldehydes formed from LOOH (<xref ref-type="bibr" rid="bib12">Cripps et al., 2017</xref>; <xref ref-type="bibr" rid="bib18">Everaert et al., 2013</xref>). Rather than acting to suppress the lipid peroxidation process, L-carnosine binds to reactive lipid aldehydes to neutralize carbonyl stress. Similar to ferrostatin-1, L-carnosine was sufficient to suppress 4-HNE and rescue cell death induced by GPx4 KD (<xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2D–F</xref>) or erastin (<xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2G–I</xref>). Leveraging these data, we performed a preclinical trial for L-carnosine provided in drinking water ad lib (80 mM) in young wildtype C57BL6/J mice. L-carnosine treatment did not alter body mass, body composition, food intake, and water intake (<xref ref-type="fig" rid="fig8s3">Figure 8—figure supplement 3A–D</xref>), and successfully suppressed 4-HNE induced by HU (<xref ref-type="fig" rid="fig8s3">Figure 8—figure supplement 3E, F</xref>). Remarkably, mice provided with L-carnosine were partly protected from disuse-induced atrophy in soleus muscles (<xref ref-type="fig" rid="fig8s3">Figure 8—figure supplement 3G</xref>).</p><p>In humans, L-carnosine is rapidly degraded by a circulating carnosinase (<xref ref-type="bibr" rid="bib4">Boldyrev et al., 2013</xref>) that may render oral carnosine treatment ineffective. In contrast, <italic>N</italic>-acetylcarnosine has a longer half-life and may be a more effective reagent in humans thus improving its translational potential. Similar to ferrostatin-1 and L-carnosine, <italic>N</italic>-acetylcarnosine also prevented 4-HNE and cell death induced by GPx4 KD (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1A–C</xref>) or erastin (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1D–F</xref>). Thus, we proceeded with a preclinical trial for <italic>N</italic>-acetylcarnosine in drinking water (80 mM, <xref ref-type="fig" rid="fig9">Figure 9A</xref>) in young (4 months, C57BL6/J; Jax colony) and old (20 months, C57BL/6; NIA rodent colony) wildtype mice. Similar to L-carnosine treatment, <italic>N</italic>-acetylcarnosine did not alter body mass, body composition, food intake, or water intake (<xref ref-type="fig" rid="fig9s2">Figure 9—figure supplement 2A–E</xref>), and successfully suppressed muscle 4-HNE (<xref ref-type="fig" rid="fig9">Figure 9B</xref> and <xref ref-type="fig" rid="fig9s2">Figure 9—figure supplement 2F, G</xref>). Strikingly, similar to our findings in GPx4Tg mice, <italic>N</italic>-acetylcarnosine ameliorated atrophy in soleus (<xref ref-type="fig" rid="fig9">Figure 9C</xref> and <xref ref-type="fig" rid="fig9s2">Figure 9—figure supplement 2H</xref>) and weakness in both soleus and EDL (<xref ref-type="fig" rid="fig9">Figure 9D</xref> and <xref ref-type="fig" rid="fig9s2">Figure 9—figure supplement 2I–K</xref>) in both young and old mice. Protection from muscle atrophy was similarly explained by greater myofiber CSA regardless of fiber type (<xref ref-type="fig" rid="fig9">Figure 9E, F</xref> and <xref ref-type="fig" rid="fig9s2">Figure 9—figure supplement 2L, M</xref>).</p><fig-group><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Pharmacological suppression of carbonyl stress ameliorates muscle atrophy and weakness in young and old mice.</title><p>(<bold>A</bold>) Schematic illustration of the protocol for administration of <italic>N</italic>-acetylcarnosine in vivo. (<bold>B</bold>) Immunoblotting of 4-hydroxynonenal (4-HNE) in gastrocnemius muscles from <italic>N</italic>-acetylcarnosine treatment in old mice. (<bold>C</bold>) Soleus muscle mass from young or old mice with or without <italic>N</italic>-acetylcarnosine treatment (n<italic>=</italic>6–8 per young group, n<italic>=</italic>7 per old group). (<bold>D</bold>) Force-frequency curve from <italic>N</italic>-acetylcarnosine study in old mice (n<italic>=</italic>4–5 per group). (<bold>E, F</bold>) Representative images of MHC immunofluorescence (<bold>E</bold>) and muscle fiber cross-sectional area (CSA) by fiber type (<bold>F</bold>) for soleus muscles (n<italic>=</italic>3–4 per group) in old mice from the <italic>N</italic>-acetylcarnosine study. Data from <italic>N</italic>-acetylcarnosine experiments are from male and female mice. Data are shown as the mean ± SEM. Statistical analyses in (<bold>C, D</bold>) and (<bold>F</bold>) were performed with a two-way analysis of variance (ANOVA) and were performed using Tukey’s (<bold>C, F</bold>) or Sidak’s (<bold>D</bold>) multiple comparisons tests.</p><p><supplementary-material id="fig9sdata1"><label>Figure 9—source data 1.</label><caption><title>Original western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig9-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig9-v2.tif"/></fig><fig id="fig9s1" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 1.</label><caption><title>Effects of <italic>N</italic>-acetylcarnosine treatment in vitro.</title><p>(<bold>A, B, C</bold>) Immunoblotting (<bold>A</bold>) and quantification (<bold>B</bold>) for 4-hydroxynonenal (4-HNE), glutathione peroxidase 4 (GPx4), and actin (n<italic>=</italic>3 per group) and cell death level (n<italic>=</italic>3 independent repeats) (<bold>C</bold>) from C2C12 myotubes with or without GPx4 KD and/or <italic>N</italic>-acetylcarnosine. (<bold>D, E, F</bold>) Immunoblotting (<bold>D</bold>) and quantification (<bold>E</bold>) of 4-HNE and actin (n<italic>=</italic>3 per group) and cell death level (n<italic>=</italic>3 independent repeats) (<bold>F</bold>) in C2C12 myotubes with or without erastin and/or <italic>N</italic>-acetylcarnosine. Data are shown as the mean ± SEM. Statistical analyses in (<bold>B</bold>) and (<bold>C</bold>) were performed with a two-way analysis of variance (ANOVA) and Tukey’s multiple comparison test. Statistical analyses in (<bold>E</bold>) and (<bold>F</bold>) were performed with a one-way ANOVA and Tukey’s multiple comparison test.</p><p><supplementary-material id="fig9s1sdata1"><label>Figure 9—figure supplement 1—source data 1.</label><caption><title>Original western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig9-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig9-figsupp1-v2.tif"/></fig><fig id="fig9s2" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 2.</label><caption><title>Additional data from <italic>N</italic>-acetylcarnosine treatment in vivo.</title><p>(<bold>A, B, C</bold>) Body mass (<bold>A</bold>), body composition from young mice (<bold>B</bold>) and old mice (<bold>C</bold>). (<bold>D, E, F, G</bold>) Food intake (<bold>D</bold>), water intake (<bold>E</bold>) (young: n<italic>=</italic>6 for vehicle sham, n<italic>=</italic>8 for <italic>N</italic>-acetylcarnosine sham, n<italic>=</italic>6 for vehicle hindlimb unloading (HU), n<italic>=</italic>7 for <italic>N</italic>-acetylcarnosine HU. Old: n<italic>=</italic>7 for vehicle sham, n<italic>=</italic>7 for <italic>N</italic>-acetylcarnosine sham, n<italic>=</italic>6 for vehicle HU, n<italic>=</italic>7 for <italic>N</italic>-acetylcarnosine HU). Immunoblotting (<bold>F</bold>) and quantification (<bold>G</bold>) of 4-hydroxynonenal (4-HNE) in gastrocnemius muscles (n<italic>=</italic>3 per group). (<bold>H</bold>) Extensor digitorum long (EDL) muscle mass from young mice and old mice. (<bold>I</bold>) Force-frequency curve in soleus muscle from young mice (n<italic>=</italic>5 for vehicle sham, n<italic>=</italic>6 for <italic>N</italic>-acetylcarnosine sham, n<italic>=</italic>5 for vehicle HU, n<italic>=</italic>5 for <italic>N</italic>-acetylcarnosine HU). (<bold>J, K</bold>) Force-frequency curve in EDL muscle from young mice (n<italic>=</italic>7 for vehicle sham, n<italic>=</italic>7 for <italic>N</italic>-acetylcarnosine sham, n<italic>=</italic>6 for vehicle HU, n<italic>=</italic>7 for <italic>N</italic>-acetylcarnosine HU) (<bold>J</bold>) and old mice (n<italic>=</italic>6 for vehicle sham, n<italic>=</italic>7 for <italic>N</italic>-acetylcarnosine sham, n<italic>=</italic>6 for vehicle HU, n<italic>=</italic>6 for <italic>N</italic>-acetylcarnosine HU) (<bold>K</bold>). (<bold>L, M</bold>) Average of muscle fiber cross-sectional area (CSA) (<bold>l</bold>) and fiber-type composition (<bold>M</bold>) for soleus muscles from old mice following HU (n<italic>=</italic>3 for vehicle, n<italic>=</italic>4 for <italic>N</italic>-acetylcarnosine). Data from <italic>N</italic>-acetylcarnosine experiments are from male and female mice. Data are shown as the mean ± SEM. Statistical analyses in (<bold>L</bold>) were performed with an unpaired two-tailed t-test. Statistical analyses in (<bold>A, B, C, D, E, G, H, I, J, K</bold>) and (<bold>M</bold>) were performed with a two-way analysis of variance (ANOVA) and Tukey’s multiple comparison test.</p><p><supplementary-material id="fig9s2sdata1"><label>Figure 9—figure supplement 2—source data 1.</label><caption><title>Original blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85289-fig9-figsupp2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85289-fig9-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The current findings demonstrate a novel mechanism that indicate LOOH as a key downstream molecule by which oxidative stress promotes muscle atrophy and weakness. Skeletal muscle LOOH was robustly upregulated with aging and disuse, and genetic or pharmacological neutralization of LOOH and their secondary reactive lipid aldehydes was sufficient to rescue muscle atrophy and weakness. In particular, <italic>N</italic>-acetylcarnosine treatment shows a potent effect in preserving muscle mass and strength with disuse in both young and old mice, informing the potential trial to utilize this compound to ameliorate loss of muscle function in humans.</p><p>During the preparation of this manuscript, Van Remmen and colleagues published a complementary study demonstrating that liproxstatin-1 can suppress denervation-induced skeletal muscle atrophy (<xref ref-type="bibr" rid="bib6">Brown et al., 2022</xref>). Denervation and HU elicits different but overlapping response in myofibers, and our studies demonstrate that their effects to drive skeletal muscle atrophy might converge on lipid peroxidation. Like ferrostatin-1, liproxstatin-1 acts to suppress the propagation of lipid peroxidation rather than acting directly on LOOH. Nevertheless, in vivo liproxstatin-1 treatment was highly effective in suppressing denervation-induced LOOH as well as reactive lipid aldehydes 4-HNE, suggesting that targeting lipid peroxidation is likely an equally effective strategy to suppress LOOH production in skeletal muscle. Conversely, our data with GPx4 overexpression and <italic>N</italic>-acetylcarnosine treatment indicate that the effect of lipid peroxidation to promote muscle atrophy is mediated by LOOH and their lipid reactive aldehydes. Neither liproxstatin-1 nor ferrostatin-1 are currently FDA-approved, but it is worthwhile to consider these drugs along with <italic>N</italic>-acetylcarnosine as potential therapeutics to treat disuse-induced muscle atrophy.</p><p>Inhibition of the autophagy-lysosomal axis prevented myotube atrophy induced by erastin or GPx4 deletion, and muscle atrophy and weakness induced by HU in vivo. These findings are in contrast with previous studies that have shown inhibition of autophagy accelerates muscle mass (<xref ref-type="bibr" rid="bib8">Carnio et al., 2014</xref>; <xref ref-type="bibr" rid="bib9">Castets et al., 2013</xref>; <xref ref-type="bibr" rid="bib33">Masiero et al., 2009</xref>). We do not interpret these differences as a discrepancy. In our studies, both inhibition of autophagy-lysosomal axis and induction of LOOH (in vitro or HU) were performed short term. It is likely that ATG3-MKO mice will eventually begin to undergo muscle atrophy similar to the muscle-specific ATG7 knockout model (<xref ref-type="bibr" rid="bib33">Masiero et al., 2009</xref>). Importantly, inhibition of the autophagy-lysosomal axis not only inhibited muscle atrophy but also the accumulation of LOOH. The exact mechanism of the role of the lysosome in LOOH propagation is unclear, but our preliminary evidence shows LOOH accumulation occurring near the lysosome. Further studies are needed to clarify the exact nature of this interaction.</p><p>Sarcopenia is an age-associated decline in muscle mass and strength, that occurs due to a combination of inactivity, injury, and/or surgery, in addition to the biological consequences of aging itself. In the current study, mice were studied at 4 or 20 months of age. While not statistically compared directly (these experiments were not performed side-by-side), skeletal muscle mass at 20 months of age was not significantly lower compared to those at 4 months of age. Thus, the current data is unclear whether genetic or pharmacological suppression of LOOH prevents the loss of muscle mass due to the biological effect of aging in the absence of HU. We chose to study mice with 20 months of age for two reasons. First, mice greater than 20 months of age do not tolerate the HU intervention well, often resulting in their inability to consume food or water. Because disuse is an integral component of human aging, we wanted to study how muscles from old mice respond to disuse. This therefore compromised our ability to study sarcopenia without disuse. Second, while muscle mass was not diminished at 20 months of age, skeletal muscle force-generating capacity was lower in 20-month-old mice compared to the 4-month-old mice, particularly in the extensor digitorum longus (EDL) muscles. In GPx4Tg mice, age-associated decrease in muscle strength (in non-HU mice) appeared to be rescued, while short-term treatment with <italic>N</italic>-acetylcarnosine had no effect. We are currently following up on these results with a long-term treatment of <italic>N</italic>-acetylcarnosine with age that display the loss of muscle mass independent of HU to see if such intervention might alleviate the loss of muscle mass and strength due to the effect of aging per se. Studies in mice greater than 20 months of age would be necessary to more definitively show the role of LOOH in sarcopenia.</p><p>We initially set out to investigate the role of LOOH in age- and disuse-induced skeletal muscle atrophy, while measuring force-generating capacity as a secondary outcome. However, in all experimental models in which accumulation of muscle LOOH was suppressed (young and old GPx4Tg mice, young and old mice with <italic>N</italic>-acetylcarnosine, and young ATG3-MKO mice), force-generating capacity (i.e., specific force normalized to CSA) was more robustly rescued compared to skeletal muscle mass. This suggests the role of LOOH to induce muscle weakness independent of muscle atrophy, and likely independent of muscle protein degradation. While out of the scope for the current study, it would be important to determine whether reactive lipid aldehydes induced by aging or disuse preferentially bind to enzymes of skeletal muscle contraction or excitation-contraction coupling to compromise their activities. As described in the previous paragraph, aging promoted muscle weakness prior to atrophy. Similarly, muscle atrophy induced by cancer cachexia is also preceded by muscle weakness (<xref ref-type="bibr" rid="bib13">Delfinis et al., 2022</xref>). Thus, these observations highlight the need to better study the mechanisms that regulate force-generating capacity independent of muscle mass.</p><p>In conclusion, we provide evidence that LOOH contributes to the loss of muscle mass and strength associated with age and disuse. Neutralization of LOOH, particularly their reactive lipid aldehyde byproducts, attenuates muscle atrophy and weakness. The mechanisms by which LOOH contributes to these phenotypes are not entirely clear, but they include protein degradation mediated by the autophagy-lysosomal axis, as well as loss in the force-generating capacity that is likely mediated by carbonyl stress. Last, but not least, these promising observations inform a potential clinical trial to test the efficacy of <italic>N</italic>-acetylcarnosine treatment in ameliorating muscle atrophy in humans.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">4-Hydroxynonenal (4-HNE)<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Ab48506</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Actin<break/>(Rabbit Polyclonal)</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">A2066</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 647-conjugated secondary<break/>(Goat Anti-Mouse Polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">A21242</td><td align="left" valign="bottom">IF<break/>(1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 568-conjugated secondary<break/>(Donkey Anti-Mouse Polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Ab175472</td><td align="left" valign="bottom">IF<break/>(1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 555-conjugated secondary<break/>(Goat Anti-Mouse Polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">A21426</td><td align="left" valign="bottom">IF<break/>(1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 488-conjugated secondary<break/>(Donkey Anti-Rabbit Polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Ab150073</td><td align="left" valign="bottom">IF<break/>(1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 488-conjugated secondary<break/>(Goat Anti-Mouse Polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">A21121</td><td align="left" valign="bottom">IF<break/>(1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">GAPDH<break/>(Rabbit Monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">14C10</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">GPx4<break/>(Rabbit Monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Ab125066</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">LAMP-2<break/>(Rabbit Polyclonal)</td><td align="left" valign="bottom">Novus</td><td align="left" valign="bottom">NB300-591</td><td align="left" valign="bottom">IF<break/>(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">LC3B<break/>(Mouse Monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">83506</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Myosin Heavy Chain Type I<break/>(Mouse Monoclonal)</td><td align="left" valign="bottom">DSHB</td><td align="left" valign="bottom">BA.D5</td><td align="left" valign="bottom">IF<break/>(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Myosin Heavy Chain Type IIA<break/>(Mouse Monoclonal)</td><td align="left" valign="bottom">DSHB</td><td align="left" valign="bottom">SC.71</td><td align="left" valign="bottom">IF<break/>(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Myosin Heavy Chain Type IIB<break/>(Mouse Monoclonal)</td><td align="left" valign="bottom">DSHB</td><td align="left" valign="bottom">BF.F3</td><td align="left" valign="bottom">IF<break/>(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">P62<break/>(Mouse Monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Ab56416</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Biological Sample (Human)</td><td align="left" valign="bottom">Human Muscle Biopsy Samples</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib40">Tanner et al., 2015</xref><break/><xref ref-type="bibr" rid="bib38">Reidy et al., 2017</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell Line, (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">C2C12 Myoblasts</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-1772</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell Line, (Human)</td><td align="left" valign="bottom">HEK293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CTRL-3216</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">C57BL/6J; Wild Type (WT)</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="char" char="." valign="bottom">000664</td><td align="left" valign="bottom">Male and Female</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">GPx4 heterogeneous KO (<italic>Gpx4</italic><sup>+/-</sup>)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib44">Yant et al., 2003</xref>.</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">GPx4 overexpression (GPx4Tg)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib37">Ran et al., 2004</xref>.</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">GPx4 conditional KO (GPx4 cKO lox/lox)</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="char" char="." valign="bottom">027964</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">ATG3 conditional KO (ATG3 cKO lox/lox)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib7">Cai et al., 2018</xref>.</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">HSA-MerCreMer<sup>+/-</sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib34">McCarthy et al., 2012</xref>.</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Gpx4 sh</italic>RNA</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">TRCN0000076552</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Lpcat3 sh</italic>RNA</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">TRCN0000121437</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Atg3 sh</italic>RNA</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">TRCN0000247442</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA Reagent</td><td align="left" valign="bottom">Packaging Vector psPAX2</td><td align="left" valign="bottom">Addgene</td><td align="char" char="." valign="bottom">12260</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA Reagent</td><td align="left" valign="bottom">Envelope Vector pMD2.G</td><td align="left" valign="bottom">Addgene</td><td align="char" char="." valign="bottom">12259</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Scrambled shRNA plasmid</td><td align="left" valign="bottom">Addgene</td><td align="char" char="." valign="bottom">1864</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Gpx4</italic> Fwd Primer</td><td align="left" valign="bottom">U of U Genomics Core</td><td align="left" valign="bottom">GCTGAGAATTCGTGCATGG</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Gpx4</italic> Rev Primer</td><td align="left" valign="bottom">U of U Genomics Core</td><td align="left" valign="bottom">CCGTCTGAGCCGCTTACTTA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Atg3</italic> Fwd Primer</td><td align="left" valign="bottom">U of U Genomics Core</td><td align="left" valign="bottom">ACACGGTGAAGGGAAAGGC</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Atg3</italic> Rev Primer</td><td align="left" valign="bottom">U of U Genomics Core</td><td align="left" valign="bottom">TGGTGGACTAAGTGATCTCCAG</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Chac1</italic> Fwd Primer</td><td align="left" valign="bottom">U of U Genomics Core</td><td align="left" valign="bottom">CTGTGGATTTTCGGGTACGG</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Chac1</italic> Rev Primer</td><td align="left" valign="bottom">U of U Genomics Core</td><td align="left" valign="bottom">CCCCTATGGAAGGTGTCTCC</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Ptgs2</italic> Fwd Primer</td><td align="left" valign="bottom">U of U Genomics Core</td><td align="left" valign="bottom">TGAGCAACTATTCCAAACCAGC</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Ptgs2</italic> Rev Primer</td><td align="left" valign="bottom">U of U Genomics Core</td><td align="left" valign="bottom">GCACGTAGTCTTCGATCACTATC</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Lpcat3</italic> Fwd Primer</td><td align="left" valign="bottom">U of U Genomics Core</td><td align="left" valign="bottom">GGCCTCTCAATTGCTTATTTCA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Lpcat3</italic> Rev Primer</td><td align="left" valign="bottom">U of U Genomics Core</td><td align="left" valign="bottom">AGCACGACACATAGCAAGGA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Auranofin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">A6733</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">BaFA1</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">SML1661</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Erastin</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">E7781</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ferrostatin-1</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">SML0583</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">L-carnosine</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">C9625</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom"><italic>N</italic>-acetylcarnosine</td><td align="left" valign="bottom">Cayman Chemical</td><td align="char" char="." valign="bottom">18817</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">RSL3</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">SLM2234</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">MDA Lipid Peroxidation Assay</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Ab118970</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism 9.3</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom">NIH</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animal models</title><p><italic>Gpx4</italic><sup>+/-</sup> and GPx4Tg mice were generated previously (<xref ref-type="bibr" rid="bib44">Yant et al., 2003</xref>; <xref ref-type="bibr" rid="bib37">Ran et al., 2004</xref>). Conditional GPx4 knockout (GPx4cKO lox/lox) mice were acquired from Jackson Laboratory (Stock No: 027964) (<xref ref-type="bibr" rid="bib45">Yoo et al., 2012</xref>). Conditional ATG3 knockout (ATG3cKO lox/lox) mice were previously described (<xref ref-type="bibr" rid="bib7">Cai et al., 2018</xref>). GPx4cKO lox/lox mice or ATG3cKO lox/lox mice were then crossed with tamoxifen-inducible, skeletal muscle-specific Cre recombinase (HSA-MerCreMer<sup>+/-</sup>) mice (<xref ref-type="bibr" rid="bib34">McCarthy et al., 2012</xref>) to generate GPx4cKO lox/lox; HSAMerCreMer<sup>-/-</sup> (control) and GPx4cKO lox/lox; HSA-MerCreMer<sup>+/-</sup> (skeletal muscle-specific GPx4 knockout; GPx4-MKO) mice or ATG3cKO lox/lox; HSAMerCreMer<sup>-/-</sup> (control) and ATG3cKO lox/lox; HSA-MerCreMer<sup>+/-</sup> (ATG3-MKO) mice. Tamoxifen-injected (7.5 μg/g body mass, 5 consecutive days) littermates were used. Mice were maintained on a 12 hr light/12 hr dark cycle in a temperature-controlled room. Body composition measurements were taken immediately before terminal experiments with a Bruker Minispec MQ20 nuclear magnetic resonance analyzer (Bruker, Rheinstetten, Germany). All mice were bred onto C57BL/6J background and were born at normal Mendelian ratios. Body mass were measured every day during HU. All experiments were randomized and blinded where appropriate. No data were excluded from the study and ARRIVE guidelines 2.0 has been followed. All protocols were approved by Institutional Animal Care and Use Committees at the University of Utah (#20-07007).</p></sec><sec id="s4-2"><title>Human skeletal muscle samples</title><p>Skeletal muscle biopsy samples from human bedrest studies were collected from a previous study (<xref ref-type="bibr" rid="bib32">Mahmassani et al., 2019</xref>). Informed consent and consent to publish was obtained from subjects. The study was reviewed and approved by the University of Utah Institutional Review Board and conformed to the Declaration of Helsinki and Title 45, US Code of Federal Regulations, Part 46, ‘Protection of Human Subjects’.</p></sec><sec id="s4-3"><title>Hindlimb unloading</title><p>Mice underwent 1, 7, or 14 days of HU (2 mice/cage) using a previously described protocol (<xref ref-type="bibr" rid="bib16">Eshima et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Heden et al., 2019</xref>) based on the traditional Morey-Holton design to study disuse atrophy in rodents. Along with daily monitoring of body mass, food intake was monitored every other day to ensure that the mice did not experience excessive weight loss due to malnutrition or dehydration. Following 1, 7, or 14 days of HU, mice were fasted for 4 hr (to avoid mice feeding immediately prior to terminal experiments) and given an intraperitoneal injection of 80 mg/kg ketamine and 10 mg/kg xylazine, after which tissues were harvested. EDL and soleus were carefully dissected for weight measurements.</p></sec><sec id="s4-4"><title>Muscle force generation</title><p>Force-generating properties of soleus and EDL muscles were measured as previously described (<xref ref-type="bibr" rid="bib19">Ferrara et al., 2018</xref>; <xref ref-type="bibr" rid="bib41">Verkerke et al., 2019</xref>). Briefly, soleus/EDL muscles were sutured at each tendon, and muscles were suspended at optimal length (Lo), which was determined by pulse stimulation. After Lo was identified, muscles were stimulated (0.35 s, pulse width 0.2 ms) at frequencies ranging from 10 to 200 Hz. Muscle length and mass were measured to quantify CSA for force normalization.</p></sec><sec id="s4-5"><title>Quantitative reverse transcription PCR</title><p>Samples were homogenized in TRIzol reagent (Life Technologies) to extract total RNA. One microgram RNA was reverse-transcribed using an IScript cDNA synthesis kit (Bio-Rad). Reverse transcription PCR was performed with the Viia 7 Real-Time PCR System (Life Technologies) using SYBR Green reagent (Life Technologies). All data were normalized to ribosomal L32 gene expression and were normalized to the mean of the control group. Primers were based on sequences in public databases.</p></sec><sec id="s4-6"><title>Western blot</title><p>Whole muscle or cells were homogenized, and western blots were performed as previously described (<xref ref-type="bibr" rid="bib16">Eshima et al., 2020</xref>). Protein homogenates were analyzed for abundance of phosphorylated 4-HNE (ab48506; Abcam), GPx4 (ab125066, Abcam), actin (A2066, MilliporeSigma), GAPDH (14C10, Cell Signaling Technology), p62 (ab56416, Abcam), LC3B (83506, Cell Signaling Technology).</p></sec><sec id="s4-7"><title>Mass spectrometry</title><p>Oxidolipidomics samples were analyzed on the SCIEX 7500 system coupled with ExionLC (SCIEX, Concord, Canada) using multiple reaction monitoring analysis. Mobile phase A is composed of 93:7 acetonitrile:dichloromethane containing 2 mM ammonium acetate and mobile phase B is composed of 50:50 acetonitrile:water containing 2 mM ammonium acetate. A Phenomenex Luna NH2 column with 3 µm particle size (4.6×150 mm<sup>2</sup>) was used for separation and column temperature was kept at 40°C. The total flow rate is 0.7 mL/min with a total run time of 17 min. Samples were extracted using the Bligh and Dyer method. Lower layer was collected, dried down, and resuspended in mobile phase A.</p></sec><sec id="s4-8"><title>Cell culture</title><p>C2C12 myoblasts and HEK293T cells were obtained and authenticated by ATCC, and tested negative for mycoplasma contamination. Both cell lines were grown and maintained in high-glucose Dulbecco’s modified Eagle’s medium (DMEM), with 10% fetal bovine serum, and 0.1% penicillin/streptomycin. Once 90–100% confluent, C2C12 cells were differentiated into myotubes with low-glucose DMEM, with L-glutamine and 110 mg/L sodium pyruvate, supplemented with 2% horse serum, and 0.1% penicillin-streptomycin. For experiments with erastin (E7781, MilliporeSigma), Ferrostatin-1 (SML0583, MilliporeSigma), and RSL3 (SML2234, MilliporeSigma), C2C12 myotubes were incubated with either 10 μM erastin/10 µM ferrostatin-1/5 μM RSL3/or equal-volume DMSO directly dissolved into medium. For experiments with L-carnosine (C9625, MilliporeSigma), and <italic>N</italic>-acetylcarnosine (18817, Cayman), C2C12 myotubes were incubated with 10 mM of L-carnosine/<italic>N</italic>-acetylcarnosine directly dissolved into medium.</p></sec><sec id="s4-9"><title>Lentivirus-mediated KD of GPx4/LPCAT3/ATG3</title><p>Lentivirus-mediated KD of experiments were performed as previously described (<xref ref-type="bibr" rid="bib24">Heden et al., 2019</xref>; <xref ref-type="bibr" rid="bib20">Ferrara et al., 2021a</xref>; <xref ref-type="bibr" rid="bib27">Johnson et al., 2020</xref>). Vectors were decreased using pLKO.1 lentiviral-RNAi system. Plasmids encoding short hairpin RNA (<italic>sh</italic>RNA) for mouse <italic>Gpx4</italic> (<italic>shGpx4</italic>: TRCN0000076552), mouse <italic>Lpcat3</italic> (<italic>shLpcat3</italic>: TRCN0000121437), and mouse <italic>Atg3</italic> (<italic>shAtg</italic>3: TRCN0000247442) were obtained from MilliporeSigma. Packaging vector psPAX2 (ID 12260), envelope vector pMD2.G (ID 12259), and scrambled <italic>sh</italic>RNA plasmid (SC: ID 1864) were obtained from Addgene. HEK293T cells in 10 cm dishes were transfected using 50 μL 0.1% polyethylenimine, 200 μL 0.15 M sodium chloride, and 500 μL Opti-MEM (with HEPES, 2.4 g/L sodium bicarbonate, and L-glutamine; Gibco 31985) with 2.66 μg of psPAX2, 0.75 μg of pMD2.G, and 3 μg of either scrambled or <italic>Gpx4</italic>/<italic>Lpcat3</italic>/<italic>Atg3 sh</italic>RNA plasmids. After 48 hr, growth media were collected and filtered using 0.22 µm vacuum filters to prepare the viral media. Because C2C12 cells are less prone to infection when differentiated, we incubated C2C12 cells in the viral media simultaneous to differentiation (days 1–3). To ensure that only cells infected with <italic>sh</italic>RNA vectors were viable, cells were selected with puromycin throughout differentiation.</p></sec><sec id="s4-10"><title>Measurements of myotube diameter</title><p>Images of myotubes were visualized at ×20 magnification using an inverted light microscope and captured with a camera (DP74, Olympus). Myotube diameter was measured for at least 100 myotubes in each group (five random fields per well, three wells per experiment, repeated at least three times) using ImageJ software. The average diameter per myotube was calculated as the mean of 10 short-axis measurements taken along the length of the myotube.</p></sec><sec id="s4-11"><title>Assessment of cell death</title><p>Cell death levels were examined by counting the numbers of cells with trypan blue staining. The cells were trypsinized and stained with 0.2% trypan blue for 5 min. Stained and non-stained cells were counted under a microscope using a hemocytometer.</p></sec><sec id="s4-12"><title>Immunofluorescence</title><p>C2C12 myotubes were fixed with 4% paraformaldehyde for 10 min and permeabilized with 0.2% Triton X-100 for 15 min. After blocking with bovine serum albumin, immunocytochemistry was performed with anti-HNE (ab48506, Abcam), anti-lysosome-associated membrane protein 2 (Lamp-2) (NB300-591, Novus), and Alexa Fluor-conjugated secondary antibodies Alexa Fluor 568 (ab175472, abcam), Alexa Fluor 488 (ab150073, abcam), and DAPI (D1306, Invitrogen). Images were captured using a 63×1.4 NA oil immersion objective on a Leica SP5 confocal system (Leica). For an experiment, C2C12 myotubes incubated with erastin with or without pretreatment of BaFA1 (SML1661, MilliporeSigma). Soleus muscles were embedded in optimal cutting temperature gel and sectioned at 10 µm with a cryostat (Microtome Plus). The sections underwent blocking for 1 hr with M.O.M. mouse IgG Blocking Reagent (Vector Laboratories, MKB-2213), 1 hr with primary antibodies (BA.D5, SC.71, BF.F3 all at 1:100 from DSHB). Sections were then probed with the following secondary antibodies: Alexa Fluor 647 (1:250; Invitrogen, A21242), Alexa Fluor 488 (1:500; Invitrogen, A21121), and Alexa Fluor 555 (1:500; Invitrogen, A21426). Negative stained fibers were considered to be IIx. Slides were imaged with an automated wide-field light microscope (Nikon Corp) using a 10× objective lens. CSA and fiber-type composition was then quantified utilizing ImageJ software.</p></sec><sec id="s4-13"><title>Mitochondrial respiration measurements</title><p>Mitochondrial O<sub>2</sub> utilization was measured using the Oroboros O<sub>2</sub>K Oxygraphs, as previously described (<xref ref-type="bibr" rid="bib16">Eshima et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Heden et al., 2019</xref>). Isolated mitochondria were added to the oxygraph chambers containing buffer Z. Respiration was measured in response to the following substrate concentrations: 0.5 mM malate, 5 mM pyruvate, 2 mM ADP, 10 mM succinate, and 1.5 μM FCCP.</p></sec><sec id="s4-14"><title>Mitochondrial H<sub>2</sub>O<sub>2</sub> measurements</title><p>Mitochondrial H<sub>2</sub>O<sub>2</sub> production was measured using the Horiba Fluoromax-4, as previously described (<xref ref-type="bibr" rid="bib16">Eshima et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Heden et al., 2019</xref>). Briefly, skeletal muscle was minced in mitochondria isolation medium (300 mM sucrose, 10 mM HEPES, 1 mM EGTA) and subsequently homogenized using a Teflon glass system. Homogenates were then centrifuged at 800 × <italic>g</italic> for 10 min, after which the supernatant was taken and centrifuged at 12,000 × <italic>g</italic> for 10 min. The resulting pellet was carefully resuspended in mitochondria isolation medium. <italic>J</italic>H<sub>2</sub>O<sub>2</sub> was measured in buffer Z (MES potassium salt; 105 mM, KCl 30 mM, KH<sub>2</sub>PO<sub>4</sub> 10 mM, MgCl<sub>2</sub> 5 mM, and BSA 0.5 mg/ml) supplemented with 10 μM Amplex UltraRed (Invitrogen) and 20 U/mL CuZnSOD in the presence of the following substrates: 10 mM succinate, 100 μM 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU/carmustine), and 1 μM auranofin. The appearance of the fluorescent product was measured with excitation/emission at 565/600 nm.</p></sec><sec id="s4-15"><title>Administration of L-carnosine/<italic>N</italic>-acetylcarnosine in vivo</title><p>Carnosine was administered as previously described (<xref ref-type="bibr" rid="bib18">Everaert et al., 2013</xref>). Briefly, young (4-month-old) or old (20-month-old) C57BL/6J mice were supplemented with 80 mM carnosine dissolved in drinking water (pH 7.5) for 2 weeks (1 week of pretreatment and 1 week during HU). Bottles were refreshed two times a week (L-carnosine, C9625, MilliporeSigma), and/or everyday (<italic>N</italic>-acetylcarnosine, 18817, Cayman).</p></sec><sec id="s4-16"><title>MDA quantification</title><p>MDA content was quantified in fresh gastrocnemius muscles using a lipid peroxidation assay kit (ab118970, Abcam) according to the manufacturer’s instruction. Rates of appearance of MDA-thiobarbituric acid adduct were quantified colorimetrically at 532 nm using a spectrophotometer.</p></sec><sec id="s4-17"><title>Statistical analyses</title><p>Data are presented as means ± SEM. Statistical and power analyses were performed using GraphPad Prism 7.03. Independent sample t-tests (two-sided) were used to compare two groups. For multiple comparisons, one- or two-way analysis of variance (ANOVA) were performed followed by appropriate post hoc tests corrected for multiple comparisons. For all tests p&lt;0.05 was considered statistically significant.</p></sec><sec id="s4-18"><title>Materials and correspondence</title><p>All newly created materials are available for sharing. Correspondence and requests should be addressed to K Funai.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>is affiliated with Sciex. The author has no financial interests to declare</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Visualization, Methodology, Writing – original draft, Project administration</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis, Validation, Investigation</p></fn><fn fn-type="con" id="con8"><p>Data curation, Formal analysis, Validation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Data curation, Formal analysis, Funding acquisition, Validation</p></fn><fn fn-type="con" id="con10"><p>Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Data curation, Formal analysis, Funding acquisition, Validation, Methodology</p></fn><fn fn-type="con" id="con12"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con13"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con14"><p>Formal analysis, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Resources, Funding acquisition, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con17"><p>Resources, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Funding acquisition, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Informed consent and consent to publish was obtained from subjects. All procedures were approved by institutional IRB at the University of Utah and conformed to the Declaration of Helsinki and Title 45, US Code of Federal Regulations, Part 46, &quot;Protection of Human Subjects.&quot;</p></fn><fn fn-type="other"><p>This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#20-07007) of the University of Utah.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-85289-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>A compulation of all uncropped western blots and genotyping gels with labels.</title></caption><media xlink:href="elife-85289-data1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This research is supported by NIH grants DK107397, DK127979, GM144613, AG074535, AG063077, (to KF), AG050781 (to MJD), HL122863, AG057006 (EJA), AG064078 (to QR), HL149870 (SB), HL139451 (to ZSM), DK130555 (to ADP), AG073493 (to JJP), American Heart Association grants 915674 (to PS), 18PRE33960491 (to ARPV), and 19PRE34380991 (to JMJ), Larry H and Gail Miller Family Foundation (to PJF), University of Utah Center on Aging Pilot Grant (to KF), and Uehara Memorial Foundation (to HE). We would like to thank Diana Lim from the University of Utah Molecular Medicine Program for assistance with figures.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>EJ</given-names></name><name><surname>Vistoli</surname><given-names>G</given-names></name><name><surname>Katunga</surname><given-names>LA</given-names></name><name><surname>Funai</surname><given-names>K</given-names></name><name><surname>Regazzoni</surname><given-names>L</given-names></name><name><surname>Monroe</surname><given-names>TB</given-names></name><name><surname>Gilardoni</surname><given-names>E</given-names></name><name><surname>Cannizzaro</surname><given-names>L</given-names></name><name><surname>Colzani</surname><given-names>M</given-names></name><name><surname>De Maddis</surname><given-names>D</given-names></name><name><surname>Rossoni</surname><given-names>G</given-names></name><name><surname>Canevotti</surname><given-names>R</given-names></name><name><surname>Gagliardi</surname><given-names>S</given-names></name><name><surname>Carini</surname><given-names>M</given-names></name><name><surname>Aldini</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A carnosine analog mitigates metabolic disorders of obesity by reducing carbonyl stress</article-title><source>The Journal of Clinical Investigation</source><volume>128</volume><fpage>5280</fpage><lpage>5293</lpage><pub-id pub-id-type="doi">10.1172/JCI94307</pub-id><pub-id pub-id-type="pmid">30226473</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>FL</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Sabia</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Jang</surname><given-names>YC</given-names></name><name><surname>Ran</surname><given-names>Q</given-names></name><name><surname>Van Remmen</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Denervation induces cytosolic phospholipase A2-mediated fatty acid hydroperoxide generation by muscle mitochondria</article-title><source>The Journal of Biological Chemistry</source><volume>284</volume><fpage>46</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1074/jbc.M806311200</pub-id><pub-id pub-id-type="pmid">19001413</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bochkov</surname><given-names>VN</given-names></name><name><surname>Oskolkova</surname><given-names>OV</given-names></name><name><surname>Birukov</surname><given-names>KG</given-names></name><name><surname>Levonen</surname><given-names>A-L</given-names></name><name><surname>Binder</surname><given-names>CJ</given-names></name><name><surname>Stöckl</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Generation and biological activities of oxidized phospholipids</article-title><source>Antioxidants &amp; Redox Signaling</source><volume>12</volume><fpage>1009</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1089/ars.2009.2597</pub-id><pub-id pub-id-type="pmid">19686040</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boldyrev</surname><given-names>AA</given-names></name><name><surname>Aldini</surname><given-names>G</given-names></name><name><surname>Derave</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Physiology and pathophysiology of carnosine</article-title><source>Physiological Reviews</source><volume>93</volume><fpage>1803</fpage><lpage>1845</lpage><pub-id pub-id-type="doi">10.1152/physrev.00039.2012</pub-id><pub-id pub-id-type="pmid">24137022</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonaldo</surname><given-names>P</given-names></name><name><surname>Sandri</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cellular and molecular mechanisms of muscle atrophy</article-title><source>Disease Models &amp; Mechanisms</source><volume>6</volume><fpage>25</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1242/dmm.010389</pub-id><pub-id pub-id-type="pmid">23268536</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JL</given-names></name><name><surname>Peelor</surname><given-names>FF</given-names></name><name><surname>Georgescu</surname><given-names>C</given-names></name><name><surname>Wren</surname><given-names>JD</given-names></name><name><surname>Kinter</surname><given-names>M</given-names></name><name><surname>Tyrrell</surname><given-names>VJ</given-names></name><name><surname>O’Donnell</surname><given-names>VB</given-names></name><name><surname>Miller</surname><given-names>BF</given-names></name><name><surname>Van Remmen</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Lipid hydroperoxides and oxylipins are mediators of denervation induced muscle atrophy</article-title><source>Redox Biology</source><volume>57</volume><elocation-id>102518</elocation-id><pub-id pub-id-type="doi">10.1016/j.redox.2022.102518</pub-id><pub-id pub-id-type="pmid">36283174</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Pires</surname><given-names>KM</given-names></name><name><surname>Ferhat</surname><given-names>M</given-names></name><name><surname>Chaurasia</surname><given-names>B</given-names></name><name><surname>Buffolo</surname><given-names>MA</given-names></name><name><surname>Smalling</surname><given-names>R</given-names></name><name><surname>Sargsyan</surname><given-names>A</given-names></name><name><surname>Atkinson</surname><given-names>DL</given-names></name><name><surname>Summers</surname><given-names>SA</given-names></name><name><surname>Graham</surname><given-names>TE</given-names></name><name><surname>Boudina</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Autophagy ablation in adipocytes induces insulin resistance and reveals roles for lipid peroxide and Nrf2 signaling in adipose-liver crosstalk</article-title><source>Cell Reports</source><volume>25</volume><fpage>1708</fpage><lpage>1717</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.10.040</pub-id><pub-id pub-id-type="pmid">30428342</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carnio</surname><given-names>S</given-names></name><name><surname>LoVerso</surname><given-names>F</given-names></name><name><surname>Baraibar</surname><given-names>MA</given-names></name><name><surname>Longa</surname><given-names>E</given-names></name><name><surname>Khan</surname><given-names>MM</given-names></name><name><surname>Maffei</surname><given-names>M</given-names></name><name><surname>Reischl</surname><given-names>M</given-names></name><name><surname>Canepari</surname><given-names>M</given-names></name><name><surname>Loefler</surname><given-names>S</given-names></name><name><surname>Kern</surname><given-names>H</given-names></name><name><surname>Blaauw</surname><given-names>B</given-names></name><name><surname>Friguet</surname><given-names>B</given-names></name><name><surname>Bottinelli</surname><given-names>R</given-names></name><name><surname>Rudolf</surname><given-names>R</given-names></name><name><surname>Sandri</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Autophagy impairment in muscle induces neuromuscular junction degeneration and precocious aging</article-title><source>Cell Reports</source><volume>8</volume><fpage>1509</fpage><lpage>1521</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.07.061</pub-id><pub-id pub-id-type="pmid">25176656</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castets</surname><given-names>P</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Rion</surname><given-names>N</given-names></name><name><surname>Di Fulvio</surname><given-names>S</given-names></name><name><surname>Romanino</surname><given-names>K</given-names></name><name><surname>Guridi</surname><given-names>M</given-names></name><name><surname>Frank</surname><given-names>S</given-names></name><name><surname>Tintignac</surname><given-names>LA</given-names></name><name><surname>Sinnreich</surname><given-names>M</given-names></name><name><surname>Rüegg</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy</article-title><source>Cell Metabolism</source><volume>17</volume><fpage>731</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.03.015</pub-id><pub-id pub-id-type="pmid">23602450</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>R</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Tang</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cellular degradation systems in ferroptosis</article-title><source>Cell Death and Differentiation</source><volume>28</volume><fpage>1135</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1038/s41418-020-00728-1</pub-id><pub-id pub-id-type="pmid">33462411</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Codenotti</surname><given-names>S</given-names></name><name><surname>Poli</surname><given-names>M</given-names></name><name><surname>Asperti</surname><given-names>M</given-names></name><name><surname>Zizioli</surname><given-names>D</given-names></name><name><surname>Marampon</surname><given-names>F</given-names></name><name><surname>Fanzani</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines</article-title><source>Journal of Cancer Research and Clinical Oncology</source><volume>144</volume><fpage>1717</fpage><lpage>1730</lpage><pub-id pub-id-type="doi">10.1007/s00432-018-2699-0</pub-id><pub-id pub-id-type="pmid">29971532</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cripps</surname><given-names>MJ</given-names></name><name><surname>Hanna</surname><given-names>K</given-names></name><name><surname>Lavilla</surname><given-names>C</given-names></name><name><surname>Sayers</surname><given-names>SR</given-names></name><name><surname>Caton</surname><given-names>PW</given-names></name><name><surname>Sims</surname><given-names>C</given-names></name><name><surname>De Girolamo</surname><given-names>L</given-names></name><name><surname>Sale</surname><given-names>C</given-names></name><name><surname>Turner</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Carnosine scavenging of glucolipotoxic free radicals enhances insulin secretion and glucose uptake</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>13313</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-13649-w</pub-id><pub-id pub-id-type="pmid">29042678</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delfinis</surname><given-names>LJ</given-names></name><name><surname>Bellissimo</surname><given-names>CA</given-names></name><name><surname>Gandhi</surname><given-names>S</given-names></name><name><surname>DiBenedetto</surname><given-names>SN</given-names></name><name><surname>Garibotti</surname><given-names>MC</given-names></name><name><surname>Thuhan</surname><given-names>AK</given-names></name><name><surname>Tsitkanou</surname><given-names>S</given-names></name><name><surname>Rosa-Caldwell</surname><given-names>ME</given-names></name><name><surname>Rahman</surname><given-names>FA</given-names></name><name><surname>Cheng</surname><given-names>AJ</given-names></name><name><surname>Wiggs</surname><given-names>MP</given-names></name><name><surname>Schlattner</surname><given-names>U</given-names></name><name><surname>Quadrilatero</surname><given-names>J</given-names></name><name><surname>Greene</surname><given-names>NP</given-names></name><name><surname>Perry</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Muscle weakness precedes atrophy during cancer cachexia and is linked to muscle-specific mitochondrial stress</article-title><source>JCI Insight</source><volume>7</volume><elocation-id>e155147</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.155147</pub-id><pub-id pub-id-type="pmid">36346680</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>SJ</given-names></name><name><surname>Lemberg</surname><given-names>KM</given-names></name><name><surname>Lamprecht</surname><given-names>MR</given-names></name><name><surname>Skouta</surname><given-names>R</given-names></name><name><surname>Zaitsev</surname><given-names>EM</given-names></name><name><surname>Gleason</surname><given-names>CE</given-names></name><name><surname>Patel</surname><given-names>DN</given-names></name><name><surname>Bauer</surname><given-names>AJ</given-names></name><name><surname>Cantley</surname><given-names>AM</given-names></name><name><surname>Yang</surname><given-names>WS</given-names></name><name><surname>Morrison</surname><given-names>B</given-names></name><name><surname>Stockwell</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Ferroptosis: an iron-dependent form of nonapoptotic cell death</article-title><source>Cell</source><volume>149</volume><fpage>1060</fpage><lpage>1072</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.03.042</pub-id><pub-id pub-id-type="pmid">22632970</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolbow</surname><given-names>DR</given-names></name><name><surname>Gorgey</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Effects of use and disuse on non-paralyzed and paralyzed skeletal muscles</article-title><source>Aging and Disease</source><volume>7</volume><fpage>68</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.14336/AD.2015.0826</pub-id><pub-id pub-id-type="pmid">26816665</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eshima</surname><given-names>H</given-names></name><name><surname>Siripoksup</surname><given-names>P</given-names></name><name><surname>Mahmassani</surname><given-names>ZS</given-names></name><name><surname>Johnson</surname><given-names>JM</given-names></name><name><surname>Ferrara</surname><given-names>PJ</given-names></name><name><surname>Verkerke</surname><given-names>ARP</given-names></name><name><surname>Salcedo</surname><given-names>A</given-names></name><name><surname>Drummond</surname><given-names>MJ</given-names></name><name><surname>Funai</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Neutralizing mitochondrial ROS does not rescue muscle atrophy induced by hindlimb unloading in female mice</article-title><source>Journal of Applied Physiology</source><volume>129</volume><fpage>124</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00456.2019</pub-id><pub-id pub-id-type="pmid">32552434</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Skeletal muscle loss: cachexia, sarcopenia, and inactivity</article-title><source>The American Journal of Clinical Nutrition</source><volume>91</volume><fpage>1123S</fpage><lpage>1127S</lpage><pub-id pub-id-type="doi">10.3945/ajcn.2010.28608A</pub-id><pub-id pub-id-type="pmid">20164314</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everaert</surname><given-names>I</given-names></name><name><surname>De Naeyer</surname><given-names>H</given-names></name><name><surname>Taes</surname><given-names>Y</given-names></name><name><surname>Derave</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Gene expression of carnosine-related enzymes and transporters in skeletal muscle</article-title><source>European Journal of Applied Physiology</source><volume>113</volume><fpage>1169</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1007/s00421-012-2540-4</pub-id><pub-id pub-id-type="pmid">23124893</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>PJ</given-names></name><name><surname>Verkerke</surname><given-names>ARP</given-names></name><name><surname>Brault</surname><given-names>JJ</given-names></name><name><surname>Funai</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hypothermia decreases O2 cost for ex vivo contraction in mouse skeletal muscle</article-title><source>Medicine and Science in Sports and Exercise</source><volume>50</volume><fpage>2015</fpage><lpage>2023</lpage><pub-id pub-id-type="doi">10.1249/MSS.0000000000001673</pub-id><pub-id pub-id-type="pmid">29787474</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>PJ</given-names></name><name><surname>Rong</surname><given-names>X</given-names></name><name><surname>Maschek</surname><given-names>JA</given-names></name><name><surname>Verkerke</surname><given-names>AR</given-names></name><name><surname>Siripoksup</surname><given-names>P</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Green</surname><given-names>TD</given-names></name><name><surname>Krishnan</surname><given-names>KC</given-names></name><name><surname>Johnson</surname><given-names>JM</given-names></name><name><surname>Turk</surname><given-names>J</given-names></name><name><surname>Houmard</surname><given-names>JA</given-names></name><name><surname>Lusis</surname><given-names>AJ</given-names></name><name><surname>Drummond</surname><given-names>MJ</given-names></name><name><surname>McClung</surname><given-names>JM</given-names></name><name><surname>Cox</surname><given-names>JE</given-names></name><name><surname>Shaikh</surname><given-names>SR</given-names></name><name><surname>Tontonoz</surname><given-names>P</given-names></name><name><surname>Holland</surname><given-names>WL</given-names></name><name><surname>Funai</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Lysophospholipid acylation modulates plasma membrane lipid organization and insulin sensitivity in skeletal muscle</article-title><source>The Journal of Clinical Investigation</source><volume>131</volume><elocation-id>e135963</elocation-id><pub-id pub-id-type="doi">10.1172/JCI135963</pub-id><pub-id pub-id-type="pmid">33591957</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>PJ</given-names></name><name><surname>Verkerke</surname><given-names>ARP</given-names></name><name><surname>Maschek</surname><given-names>JA</given-names></name><name><surname>Shahtout</surname><given-names>JL</given-names></name><name><surname>Siripoksup</surname><given-names>P</given-names></name><name><surname>Eshima</surname><given-names>H</given-names></name><name><surname>Johnson</surname><given-names>JM</given-names></name><name><surname>Petrocelli</surname><given-names>JJ</given-names></name><name><surname>Mahmassani</surname><given-names>ZS</given-names></name><name><surname>Green</surname><given-names>TD</given-names></name><name><surname>McClung</surname><given-names>JM</given-names></name><name><surname>Cox</surname><given-names>JE</given-names></name><name><surname>Drummond</surname><given-names>MJ</given-names></name><name><surname>Funai</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Low lysophosphatidylcholine induces skeletal muscle myopathy that is aggravated by high-fat diet feeding</article-title><source>FASEB Journal</source><volume>35</volume><elocation-id>e21867</elocation-id><pub-id pub-id-type="doi">10.1096/fj.202101104R</pub-id><pub-id pub-id-type="pmid">34499764</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Monian</surname><given-names>P</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Ferroptosis is an autophagic cell death process</article-title><source>Cell Research</source><volume>26</volume><fpage>1021</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1038/cr.2016.95</pub-id><pub-id pub-id-type="pmid">27514700</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>R</given-names></name><name><surname>Tang</surname><given-names>D</given-names></name><name><surname>Dai</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Ferroptosis is a lysosomal cell death process</article-title><source>Biochemical and Biophysical Research Communications</source><volume>503</volume><fpage>1550</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2018.07.078</pub-id><pub-id pub-id-type="pmid">30031610</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heden</surname><given-names>TD</given-names></name><name><surname>Johnson</surname><given-names>JM</given-names></name><name><surname>Ferrara</surname><given-names>PJ</given-names></name><name><surname>Eshima</surname><given-names>H</given-names></name><name><surname>Verkerke</surname><given-names>ARP</given-names></name><name><surname>Wentzler</surname><given-names>EJ</given-names></name><name><surname>Siripoksup</surname><given-names>P</given-names></name><name><surname>Narowski</surname><given-names>TM</given-names></name><name><surname>Coleman</surname><given-names>CB</given-names></name><name><surname>Lin</surname><given-names>C-T</given-names></name><name><surname>Ryan</surname><given-names>TE</given-names></name><name><surname>Reidy</surname><given-names>PT</given-names></name><name><surname>de Castro Brás</surname><given-names>LE</given-names></name><name><surname>Karner</surname><given-names>CM</given-names></name><name><surname>Burant</surname><given-names>CF</given-names></name><name><surname>Maschek</surname><given-names>JA</given-names></name><name><surname>Cox</surname><given-names>JE</given-names></name><name><surname>Mashek</surname><given-names>DG</given-names></name><name><surname>Kardon</surname><given-names>G</given-names></name><name><surname>Boudina</surname><given-names>S</given-names></name><name><surname>Zeczycki</surname><given-names>TN</given-names></name><name><surname>Rutter</surname><given-names>J</given-names></name><name><surname>Shaikh</surname><given-names>SR</given-names></name><name><surname>Vance</surname><given-names>JE</given-names></name><name><surname>Drummond</surname><given-names>MJ</given-names></name><name><surname>Neufer</surname><given-names>PD</given-names></name><name><surname>Funai</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mitochondrial PE potentiates respiratory enzymes to amplify skeletal muscle aerobic capacity</article-title><source>Science Advances</source><volume>5</volume><elocation-id>eaax8352</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aax8352</pub-id><pub-id pub-id-type="pmid">31535029</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichimura</surname><given-names>Y</given-names></name><name><surname>Kirisako</surname><given-names>T</given-names></name><name><surname>Takao</surname><given-names>T</given-names></name><name><surname>Satomi</surname><given-names>Y</given-names></name><name><surname>Shimonishi</surname><given-names>Y</given-names></name><name><surname>Ishihara</surname><given-names>N</given-names></name><name><surname>Mizushima</surname><given-names>N</given-names></name><name><surname>Tanida</surname><given-names>I</given-names></name><name><surname>Kominami</surname><given-names>E</given-names></name><name><surname>Ohsumi</surname><given-names>M</given-names></name><name><surname>Noda</surname><given-names>T</given-names></name><name><surname>Ohsumi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A ubiquitin-like system mediates protein lipidation</article-title><source>Nature</source><volume>408</volume><fpage>488</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/35044114</pub-id><pub-id pub-id-type="pmid">11100732</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>H</given-names></name><name><surname>Nakagawa</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPX4) in mammalian cells</article-title><source>Free Radical Biology &amp; Medicine</source><volume>34</volume><fpage>145</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/s0891-5849(02)01197-8</pub-id><pub-id pub-id-type="pmid">12521597</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JM</given-names></name><name><surname>Verkerke</surname><given-names>ARP</given-names></name><name><surname>Maschek</surname><given-names>JA</given-names></name><name><surname>Ferrara</surname><given-names>PJ</given-names></name><name><surname>Lin</surname><given-names>C-T</given-names></name><name><surname>Kew</surname><given-names>KA</given-names></name><name><surname>Neufer</surname><given-names>PD</given-names></name><name><surname>Lodhi</surname><given-names>IJ</given-names></name><name><surname>Cox</surname><given-names>JE</given-names></name><name><surname>Funai</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Alternative splicing of UCP1 by non-cell-autonomous action of PEMT</article-title><source>Molecular Metabolism</source><volume>31</volume><fpage>55</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2019.10.007</pub-id><pub-id pub-id-type="pmid">31918922</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kagan</surname><given-names>VE</given-names></name><name><surname>Mao</surname><given-names>G</given-names></name><name><surname>Qu</surname><given-names>F</given-names></name><name><surname>Angeli</surname><given-names>JPF</given-names></name><name><surname>Doll</surname><given-names>S</given-names></name><name><surname>Croix</surname><given-names>CS</given-names></name><name><surname>Dar</surname><given-names>HH</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Tyurin</surname><given-names>VA</given-names></name><name><surname>Ritov</surname><given-names>VB</given-names></name><name><surname>Kapralov</surname><given-names>AA</given-names></name><name><surname>Amoscato</surname><given-names>AA</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Anthonymuthu</surname><given-names>T</given-names></name><name><surname>Mohammadyani</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Proneth</surname><given-names>B</given-names></name><name><surname>Klein-Seetharaman</surname><given-names>J</given-names></name><name><surname>Watkins</surname><given-names>S</given-names></name><name><surname>Bahar</surname><given-names>I</given-names></name><name><surname>Greenberger</surname><given-names>J</given-names></name><name><surname>Mallampalli</surname><given-names>RK</given-names></name><name><surname>Stockwell</surname><given-names>BR</given-names></name><name><surname>Tyurina</surname><given-names>YY</given-names></name><name><surname>Conrad</surname><given-names>M</given-names></name><name><surname>Bayır</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis</article-title><source>Nature Chemical Biology</source><volume>13</volume><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2238</pub-id><pub-id pub-id-type="pmid">27842066</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katunga</surname><given-names>LA</given-names></name><name><surname>Gudimella</surname><given-names>P</given-names></name><name><surname>Efird</surname><given-names>JT</given-names></name><name><surname>Abernathy</surname><given-names>S</given-names></name><name><surname>Mattox</surname><given-names>TA</given-names></name><name><surname>Beatty</surname><given-names>C</given-names></name><name><surname>Darden</surname><given-names>TM</given-names></name><name><surname>Thayne</surname><given-names>KA</given-names></name><name><surname>Alwair</surname><given-names>H</given-names></name><name><surname>Kypson</surname><given-names>AP</given-names></name><name><surname>Virag</surname><given-names>JA</given-names></name><name><surname>Anderson</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Obesity in a model of GPX4 haploinsufficiency uncovers a causal role for lipid-derived aldehydes in human metabolic disease and cardiomyopathy</article-title><source>Molecular Metabolism</source><volume>4</volume><fpage>493</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2015.04.001</pub-id><pub-id pub-id-type="pmid">26042203</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>L</given-names></name><name><surname>Degens</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Salviati</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>YI</given-names></name><name><surname>Thompson</surname><given-names>W</given-names></name><name><surname>Kirkland</surname><given-names>JL</given-names></name><name><surname>Sandri</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sarcopenia: aging-related loss of muscle mass and function</article-title><source>Physiological Reviews</source><volume>99</volume><fpage>427</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1152/physrev.00061.2017</pub-id><pub-id pub-id-type="pmid">30427277</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J-Y</given-names></name><name><surname>Kim</surname><given-names>WK</given-names></name><name><surname>Bae</surname><given-names>K-H</given-names></name><name><surname>Lee</surname><given-names>SC</given-names></name><name><surname>Lee</surname><given-names>E-W</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Lipid metabolism and ferroptosis</article-title><source>Biology</source><volume>10</volume><elocation-id>184</elocation-id><pub-id pub-id-type="doi">10.3390/biology10030184</pub-id><pub-id pub-id-type="pmid">33801564</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmassani</surname><given-names>ZS</given-names></name><name><surname>Reidy</surname><given-names>PT</given-names></name><name><surname>McKenzie</surname><given-names>AI</given-names></name><name><surname>Stubben</surname><given-names>C</given-names></name><name><surname>Howard</surname><given-names>MT</given-names></name><name><surname>Drummond</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Age-Dependent skeletal muscle transcriptome response to bed rest-induced atrophy</article-title><source>Journal of Applied Physiology</source><volume>126</volume><fpage>894</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00811.2018</pub-id><pub-id pub-id-type="pmid">30605403</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masiero</surname><given-names>E</given-names></name><name><surname>Agatea</surname><given-names>L</given-names></name><name><surname>Mammucari</surname><given-names>C</given-names></name><name><surname>Blaauw</surname><given-names>B</given-names></name><name><surname>Loro</surname><given-names>E</given-names></name><name><surname>Komatsu</surname><given-names>M</given-names></name><name><surname>Metzger</surname><given-names>D</given-names></name><name><surname>Reggiani</surname><given-names>C</given-names></name><name><surname>Schiaffino</surname><given-names>S</given-names></name><name><surname>Sandri</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Autophagy is required to maintain muscle mass</article-title><source>Cell Metabolism</source><volume>10</volume><fpage>507</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2009.10.008</pub-id><pub-id pub-id-type="pmid">19945408</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>JJ</given-names></name><name><surname>Srikuea</surname><given-names>R</given-names></name><name><surname>Kirby</surname><given-names>TJ</given-names></name><name><surname>Peterson</surname><given-names>CA</given-names></name><name><surname>Esser</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Inducible CRE transgenic mouse strain for skeletal muscle-specific gene targeting</article-title><source>Skeletal Muscle</source><volume>2</volume><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.1186/2044-5040-2-8</pub-id><pub-id pub-id-type="pmid">22564549</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pharaoh</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>JL</given-names></name><name><surname>Sataranatarajan</surname><given-names>K</given-names></name><name><surname>Kneis</surname><given-names>P</given-names></name><name><surname>Bian</surname><given-names>J</given-names></name><name><surname>Ranjit</surname><given-names>R</given-names></name><name><surname>Hadad</surname><given-names>N</given-names></name><name><surname>Georgescu</surname><given-names>C</given-names></name><name><surname>Rabinovitch</surname><given-names>P</given-names></name><name><surname>Ran</surname><given-names>Q</given-names></name><name><surname>Wren</surname><given-names>JD</given-names></name><name><surname>Freeman</surname><given-names>W</given-names></name><name><surname>Kinter</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>A</given-names></name><name><surname>Van Remmen</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targeting cPLA2 derived lipid hydroperoxides as a potential intervention for sarcopenia</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>13968</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-70792-7</pub-id><pub-id pub-id-type="pmid">32811851</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>SK</given-names></name><name><surname>Smuder</surname><given-names>AJ</given-names></name><name><surname>Criswell</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mechanistic links between oxidative stress and disuse muscle atrophy</article-title><source>Antioxidants &amp; Redox Signaling</source><volume>15</volume><fpage>2519</fpage><lpage>2528</lpage><pub-id pub-id-type="doi">10.1089/ars.2011.3973</pub-id><pub-id pub-id-type="pmid">21457104</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname><given-names>Q</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Gu</surname><given-names>M</given-names></name><name><surname>Qi</surname><given-names>W</given-names></name><name><surname>Walter</surname><given-names>CA</given-names></name><name><surname>Roberts</surname><given-names>LJ</given-names></name><name><surname>Herman</surname><given-names>B</given-names></name><name><surname>Richardson</surname><given-names>A</given-names></name><name><surname>Van Remmen</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Transgenic mice overexpressing glutathione peroxidase 4 are protected against oxidative stress-induced apoptosis</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>55137</fpage><lpage>55146</lpage><pub-id pub-id-type="doi">10.1074/jbc.M410387200</pub-id><pub-id pub-id-type="pmid">15496407</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reidy</surname><given-names>PT</given-names></name><name><surname>McKenzie</surname><given-names>AI</given-names></name><name><surname>Brunker</surname><given-names>P</given-names></name><name><surname>Nelson</surname><given-names>DS</given-names></name><name><surname>Barrows</surname><given-names>KM</given-names></name><name><surname>Supiano</surname><given-names>M</given-names></name><name><surname>LaStayo</surname><given-names>PC</given-names></name><name><surname>Drummond</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Neuromuscular electrical stimulation combined with protein ingestion preserves thigh muscle mass but not muscle function in healthy older adults during 5 days of bed rest</article-title><source>Rejuvenation Research</source><volume>20</volume><fpage>449</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1089/rej.2017.1942</pub-id><pub-id pub-id-type="pmid">28482746</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scicchitano</surname><given-names>BM</given-names></name><name><surname>Pelosi</surname><given-names>L</given-names></name><name><surname>Sica</surname><given-names>G</given-names></name><name><surname>Musarò</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The physiopathologic role of oxidative stress in skeletal muscle</article-title><source>Mechanisms of Ageing and Development</source><volume>170</volume><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.mad.2017.08.009</pub-id><pub-id pub-id-type="pmid">28851603</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanner</surname><given-names>RE</given-names></name><name><surname>Brunker</surname><given-names>LB</given-names></name><name><surname>Agergaard</surname><given-names>J</given-names></name><name><surname>Barrows</surname><given-names>KM</given-names></name><name><surname>Briggs</surname><given-names>RA</given-names></name><name><surname>Kwon</surname><given-names>OS</given-names></name><name><surname>Young</surname><given-names>LM</given-names></name><name><surname>Hopkins</surname><given-names>PN</given-names></name><name><surname>Volpi</surname><given-names>E</given-names></name><name><surname>Marcus</surname><given-names>RL</given-names></name><name><surname>LaStayo</surname><given-names>PC</given-names></name><name><surname>Drummond</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Age-related differences in lean mass, protein synthesis and skeletal muscle markers of proteolysis after bed rest and exercise rehabilitation</article-title><source>The Journal of Physiology</source><volume>593</volume><fpage>4259</fpage><lpage>4273</lpage><pub-id pub-id-type="doi">10.1113/JP270699</pub-id><pub-id pub-id-type="pmid">26173027</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verkerke</surname><given-names>ARP</given-names></name><name><surname>Ferrara</surname><given-names>PJ</given-names></name><name><surname>Lin</surname><given-names>C-T</given-names></name><name><surname>Johnson</surname><given-names>JM</given-names></name><name><surname>Ryan</surname><given-names>TE</given-names></name><name><surname>Maschek</surname><given-names>JA</given-names></name><name><surname>Eshima</surname><given-names>H</given-names></name><name><surname>Paran</surname><given-names>CW</given-names></name><name><surname>Laing</surname><given-names>BT</given-names></name><name><surname>Siripoksup</surname><given-names>P</given-names></name><name><surname>Tippetts</surname><given-names>TS</given-names></name><name><surname>Wentzler</surname><given-names>EJ</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Spangenburg</surname><given-names>EE</given-names></name><name><surname>Brault</surname><given-names>JJ</given-names></name><name><surname>Villanueva</surname><given-names>CJ</given-names></name><name><surname>Summers</surname><given-names>SA</given-names></name><name><surname>Holland</surname><given-names>WL</given-names></name><name><surname>Cox</surname><given-names>JE</given-names></name><name><surname>Vance</surname><given-names>DE</given-names></name><name><surname>Neufer</surname><given-names>PD</given-names></name><name><surname>Funai</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Phospholipid methylation regulates muscle metabolic rate through Ca2+ transport efficiency</article-title><source>Nature Metabolism</source><volume>1</volume><fpage>876</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1038/s42255-019-0111-2</pub-id><pub-id pub-id-type="pmid">32405618</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiernicki</surname><given-names>B</given-names></name><name><surname>Dubois</surname><given-names>H</given-names></name><name><surname>Tyurina</surname><given-names>YY</given-names></name><name><surname>Hassannia</surname><given-names>B</given-names></name><name><surname>Bayir</surname><given-names>H</given-names></name><name><surname>Kagan</surname><given-names>VE</given-names></name><name><surname>Vandenabeele</surname><given-names>P</given-names></name><name><surname>Wullaert</surname><given-names>A</given-names></name><name><surname>Vanden Berghe</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Excessive phospholipid peroxidation distinguishes ferroptosis from other cell death modes including pyroptosis</article-title><source>Cell Death &amp; Disease</source><volume>11</volume><elocation-id>922</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-020-03118-0</pub-id><pub-id pub-id-type="pmid">33110056</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>WS</given-names></name><name><surname>SriRamaratnam</surname><given-names>R</given-names></name><name><surname>Welsch</surname><given-names>ME</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Skouta</surname><given-names>R</given-names></name><name><surname>Viswanathan</surname><given-names>VS</given-names></name><name><surname>Cheah</surname><given-names>JH</given-names></name><name><surname>Clemons</surname><given-names>PA</given-names></name><name><surname>Shamji</surname><given-names>AF</given-names></name><name><surname>Clish</surname><given-names>CB</given-names></name><name><surname>Brown</surname><given-names>LM</given-names></name><name><surname>Girotti</surname><given-names>AW</given-names></name><name><surname>Cornish</surname><given-names>VW</given-names></name><name><surname>Schreiber</surname><given-names>SL</given-names></name><name><surname>Stockwell</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Regulation of ferroptotic cancer cell death by GPX4</article-title><source>Cell</source><volume>156</volume><fpage>317</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.12.010</pub-id><pub-id pub-id-type="pmid">24439385</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yant</surname><given-names>LJ</given-names></name><name><surname>Ran</surname><given-names>Q</given-names></name><name><surname>Rao</surname><given-names>L</given-names></name><name><surname>Van Remmen</surname><given-names>H</given-names></name><name><surname>Shibatani</surname><given-names>T</given-names></name><name><surname>Belter</surname><given-names>JG</given-names></name><name><surname>Motta</surname><given-names>L</given-names></name><name><surname>Richardson</surname><given-names>A</given-names></name><name><surname>Prolla</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The selenoprotein GPx4 is essential for mouse development and protects from radiation and oxidative damage insults</article-title><source>Free Radical Biology &amp; Medicine</source><volume>34</volume><fpage>496</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/s0891-5849(02)01360-6</pub-id><pub-id pub-id-type="pmid">12566075</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>S-E</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Na</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Rios</surname><given-names>C</given-names></name><name><surname>Van Remmen</surname><given-names>H</given-names></name><name><surname>Richardson</surname><given-names>A</given-names></name><name><surname>Ran</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brain</article-title><source>Free Radical Biology &amp; Medicine</source><volume>52</volume><fpage>1820</fpage><lpage>1827</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.02.043</pub-id><pub-id pub-id-type="pmid">22401858</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85289.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cardozo</surname><given-names>Christopher</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2021.12.17.473200" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2021.12.17.473200"/></front-stub><body><p>This paper is of fundamental importance for its description of the role of lipid peroxidation in the loss of muscle mass and contractile function during aging and hindlimb suspension. The evidence is generally solid though is incomplete in some areas. The paper will be of particular interest to those who study the biology of aging-related muscle dysfunction.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85289.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Cardozo</surname><given-names>Christopher</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Cardozo</surname><given-names>Christopher</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.12.17.473200">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.12.17.473200v2">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Lipid hydroperoxides promote sarcopenia through carbonyl stress&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, including Christopher Cardozo as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Carlos Isales as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Please discuss further the potential limitation of using 20 month old mice, an age when age-related loss of muscle mass may not yet have appeared.</p><p>2) Please consider carefully each of the points raised by the reviewers and listed below and provide a response with your resubmission.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>I feel that addressing the following points would improve the paper.</p><p>Introduction (line 79) add mention of effects on muscle contractile function which have greater functional impact.</p><p>Line 90 revise to be more clear about these lipids. Are these the most abundant oxidized lipids for which a change was observed?</p><p>Line 91 consider adding 'species' after oxidized phosphatidylethanolamine.</p><p>Line 104 – the data shown are levels of H202 and electron leaks which are different from production of ATP / utilization of fats and carbohydrates as substrates; please consider clarifying the text.</p><p>Line 128 – it looks from the figures like the N=2-3 for supplemental Figure S3F and G please clarify the N here.</p><p>Line 156 – this is more of a comment outside of the review but please note that MG132 is a peptide aldehyde and not surprisingly for this class of inhibitors blocks action of other peptidases and proteases such as calpains. Irreversible inhibitors such as epoxymicin are quite a bit more specific.</p><p>Line 166 – The change in protein content could be explained by changes in synthesis and/or degradation. I am unclear how the experiment informs the reader about the lipidation state of these proteins. I would revise this section carefully to be more conservative.</p><p>Line 252 – I would word this less strongly as there are many published mechanisms for unloading-related and aging-related declines in muscle. The data presented here does certainly support a mechanism that raises LOOH but is not sufficient to confirm it is the primary or only one.</p><p>Line 308 – there are alternative mechanisms to consider. Impaired excitation-contraction coupling is one well-known deficit of muscle in aging.</p><p>Line 357 – why were mice fasted before euthanasia?</p><p>Line 391 – the word ‘column’ seems to be missing.</p><p>General comments on the Figures</p><p>For studies of myotubes, are the data reflective of a single experiment? Were tubes in one well or multiple wells examined? Adding this information would add to the ability of the reader to made an informed assessment of the data.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>– In all experiments, the ages and sex of the animals should be specified. For example, what is the age and sex relative to the human and mouse samples in Fig. 1A-B?</p><p>– Soleus and EDL are muscles with a different contractile properties that lead to a different response in disuse models and aging. In this study, the authors mentioned skeletal muscle in general and didn’t specify which muscle they are talking about in the results section. Please amend the manuscript accordingly.</p><list list-type="order"><list-item><p>– There is no figure S7I in the supplemental material.</p></list-item><list-item><p>– On lines #174-177, the authors mentioned that the loss of muscle ATG3 protects from disuse-induced atrophy and weakness which can be explained by greater myofiber cross-sectional area. Again, what muscle are the authors talking about? Moreover, there is no myofiber diameter data on the EDL muscle.</p></list-item><list-item><p>– In the discussion section, line#274, the authors are considering that N-acetylcarnosine as a potential therapeutic to treat muscle atrophy. I would amend the manuscript to state that the N-acetylcarnosine could be considered as a potential therapeutic to treat disuse-induced muscle atrophy because this is model of atrophy primarily used in this manuscript. Other modes of muscle atrophy may or may not be responsive to N-acetylcarnosine.</p></list-item><list-item><p>– The connection between LOOH and the autophagy-lysosomal axis should be better presented in the discussion.</p></list-item><list-item><p>– In figure S6H, the error bars are in the wrong place.</p></list-item><list-item><p>– Figures S11E and S13F are missing the loading controls.</p></list-item><list-item><p>– The confocal images in figure 7E are at low resolution – high-resolution images should be used.</p></list-item></list></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85289.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Please discuss further the potential limitation of using 20 month old mice, an age when age-related loss of muscle mass may not yet have appeared.</p></disp-quote><p>Thank you. We now provide this discussion in lines 303-305 and 315-319. We also describe below our ongoing study to address this point (response to Reviewer 2).</p><disp-quote content-type="editor-comment"><p>2) Please consider carefully each of the points raised by the reviewers and listed below and provide a response with your resubmission.</p></disp-quote><p>Our point-by-point responses are shown below.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>I feel that addressing the following points would improve the paper.</p><p>Introduction (line 79) add mention of effects on muscle contractile function which have greater functional impact.</p></disp-quote><p>Thank you for this suggestion. Our introduction has been modified to address this point (lines 77-80).</p><disp-quote content-type="editor-comment"><p>Line 90 revise to be more clear about these lipids. Are these the most abundant oxidized lipids for which a change was observed?</p></disp-quote><p>Thank you. Lipids in Figure 1D represent lipid species whose fold-increases with age was the greatest. We apologize for the confusion (lines 91-95).</p><disp-quote content-type="editor-comment"><p>Line 91 consider adding 'species' after oxidized phosphatidylethanolamine.</p></disp-quote><p>Done.</p><disp-quote content-type="editor-comment"><p>Line 104 – the data shown are levels of H202 and electron leaks which are different from production of ATP / utilization of fats and carbohydrates as substrates; please consider clarifying the text.</p></disp-quote><p>Thank you for this suggestion. We agree that this was a confusing way to describe our findings. We rephrased the sentence to “mitochondrial ROS production”.</p><disp-quote content-type="editor-comment"><p>Line 128 – it looks from the figures like the N=2-3 for supplemental Figure S3F and G please clarify the N here.</p></disp-quote><p>We are grateful for helping us identify this omission. It appears that one of the data points in the third bar of Figure 3F was accidentally omitted when copying and pasting on AI. We revised our figure (n=3 for all groups).</p><disp-quote content-type="editor-comment"><p>Line 156 – this is more of a comment outside of the review but please note that MG132 is a peptide aldehyde and not surprisingly for this class of inhibitors blocks action of other peptidases and proteases such as calpains. Irreversible inhibitors such as epoxymicin are quite a bit more specific.</p></disp-quote><p>Thank you for this comment! We were unaware about these effects of MG132 and consider alternatives for future experiments.</p><disp-quote content-type="editor-comment"><p>Line 166 – The change in protein content could be explained by changes in synthesis and/or degradation. I am unclear how the experiment informs the reader about the lipidation state of these proteins. I would revise this section carefully to be more conservative.</p></disp-quote><p>Agreed. We modified the sentence to describe the possibility that syntheses of these proteins may be affected in addition to degradation (lines 170-173).</p><disp-quote content-type="editor-comment"><p>Line 252 – I would word this less strongly as there are many published mechanisms for unloading-related and aging-related declines in muscle. The data presented here does certainly support a mechanism that raises LOOH but is not sufficient to confirm it is the primary or only one.</p></disp-quote><p>Thank you. We rephrased this sentence accordingly (lines 260-262).</p><disp-quote content-type="editor-comment"><p>Line 308 – there are alternative mechanisms to consider. Impaired excitation-contraction coupling is one well-known deficit of muscle in aging.</p></disp-quote><p>Thank you for this suggestion. We now include a discussion on excitation-contraction coupling as a potential mediator (lines 328-331).</p><disp-quote content-type="editor-comment"><p>Line 357 – why were mice fasted before euthanasia?</p></disp-quote><p>Because all mice have free access to food, any given mice could vary largely with the timing of their last food consumption. We routinely remove food prior to terminal experiments so that no mice had eaten immediately prior to tissue collection (lines 381-384).</p><disp-quote content-type="editor-comment"><p>Line 391 – the word ‘column’ seems to be missing.</p></disp-quote><p>Thank you for this correction (lines 415-417).</p><disp-quote content-type="editor-comment"><p>General comments on the Figures</p><p>For studies of myotubes, are the data reflective of a single experiment? Were tubes in one well or multiple wells examined? Adding this information would add to the ability of the reader to made an informed assessment of the data.</p></disp-quote><p>We apologize for omitting this information. We added more details in the method (lines 456-458).</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>– In all experiments, the ages and sex of the animals should be specified. For example, what is the age and sex relative to the human and mouse samples in Fig. 1A-B?</p></disp-quote><p>Thank you. We now provide this information in the figure legends.</p><disp-quote content-type="editor-comment"><p>– Soleus and EDL are muscles with a different contractile properties that lead to a different response in disuse models and aging. In this study, the authors mentioned skeletal muscle in general and didn’t specify which muscle they are talking about in the results section. Please amend the manuscript accordingly.</p></disp-quote><p>This is an excellent point. We primarily focused on soleus and EDL muscles (data on EDL muscles are primarily in the supplement as soleus had a more robust change in mass with HU) because they could be used to quantify ex vivo contractile activity, but in no way these two muscles necessarily represent all muscle types throughout the body. We modified our manuscript accordingly.</p><disp-quote content-type="editor-comment"><p>– There is no figure S7I in the supplemental material.</p></disp-quote><p>Thank you. This was our mistake and the text is referring to S7H instead (line 180).</p><disp-quote content-type="editor-comment"><p>– On lines #174-177, the authors mentioned that the loss of muscle ATG3 protects from disuse-induced atrophy and weakness which can be explained by greater myofiber cross-sectional area. Again, what muscle are the authors talking about? Moreover, there is no myofiber diameter data on the EDL muscle.</p></disp-quote><p>Thank you. We modified the text accordingly that our findings for muscle mass was in soleus and force-generating capacity in both soleus and EDL muscles (lines 179-183). We chose to section soleus only because masses of EDL was not significantly reduced by HU. For preceding figures (GPx4+/- and GPx4-MKO) where deletion of GPx4 made atrophy worse in both soleus and EDL muscles we performed the fiber-type/CSA analyses in both muscles. For ATG3-MKO, GPx4Tg, L-carnosine and N-acetylcarnosine studies where these interventions prevented the atrophy, which was only observed in soleus (largely because masses of EDL was not significantly reduced by HU), we focused our fiber-type/CSA analyses in soleus.</p><disp-quote content-type="editor-comment"><p>– In the discussion section, line#274, the authors are considering that N-acetylcarnosine as a potential therapeutic to treat muscle atrophy. I would amend the manuscript to state that the N-acetylcarnosine could be considered as a potential therapeutic to treat disuse-induced muscle atrophy because this is model of atrophy primarily used in this manuscript. Other modes of muscle atrophy may or may not be responsive to N-acetylcarnosine.</p></disp-quote><p>Thank you. We amended this phrase (lines 281-283).</p><disp-quote content-type="editor-comment"><p>– The connection between LOOH and the autophagy-lysosomal axis should be better presented in the discussion.</p></disp-quote><p>Thank you. We now add these discussions in lines 280-291.</p><disp-quote content-type="editor-comment"><p>– In figure S6H, the error bars are in the wrong place.</p></disp-quote><p>Corrected.</p><disp-quote content-type="editor-comment"><p>– Figures S11E and S13F are missing the loading controls.</p></disp-quote><p>Loading controls have now been added.</p><disp-quote content-type="editor-comment"><p>– The confocal images in figure 7E are at low resolution – high-resolution images should be used.</p></disp-quote><p>We utilized a confocal microscope at our central core facility. We currently do not have immediate access to a microscope with better resolution, but when we will perform further studies on LOOH and lysosome we will seek to obtain better images.</p></body></sub-article></article>